Abstract:
This present invention relates to calcium channel compositions. In particular, this invention relates to a mammalian gene, herein referred to as CACNA1F, encoding an (alpha) 1 F-subunit of a retinal calcium channel. Mutations of CACNA1F may cause a type of X-linked congenital stationary night blindness known as incomplete CSNB, and may also cause Aaland Island Eye Disease, which may be clinically indistinguishable from incomplete CSNB.

Description:
This application is a continuation of international application number PCT/CA99/00514, filed Jun. 2, 1999 which claimed priority to U.S. Provisional Patent application No. 60/087,635, filed of Jun. 2, 1998. 
    
    
     FIELD OF THE INVENTION 
     This present invention relates to calcium channel compositions. In particular, this invention relates to a mammalian gene encoding a retinal calcium channel subunit polypeptide, herein referred to as CACNA1F, wherein mutations of CACNA1F may cause a type of X-linked congenital stationary night blindness. 
     REFERENCES 
     The following references are cited in the application as numbers in brackets ([ ]) at the relevant portion of the application. Each of these references is incorporated herein by reference. 
     1. Héon and Musarella, “Congenital stationary night blindness: a critical review for molecular approaches”, in  Molecular Genetics of Inherited Eye Disorders  (eds. Wright, A. F. &amp; Jay, B.) pp 277-301 (Harwood Academic Publishers, London, 1994). 
     2. Miyake, et al., “Congenital stationary night blindness with negative electroretinogram”,  Arch. Ophthalmol.  104, 1013-1020 (1986). 
     3. Weleber. et al., “Aaland Island Eye Disease (Forsius-Eriksson syndrome) associated with contiguous deletion syndrome at Xp21 ”, Arch. Ophthalmol  107:1170-1179. 
     4. Boycott, et al., “Evidence for genetic heterogeneity in X-linked congenital stationary night blindness.”  Am. J. Hum. Genet.  62:865-875 (1998). 
     5. Catterall, “Structure and function of voltage-gated ion channels”.  Annu. Rev. Biochem.  64, 493-531 (1995). 
     6. Fishman and Sokol, “ Electrophysiologic Testing in Disorders of the Retina, Optic Nerve, and Visual Pathway ”, (Am. Acad. Ophthal., San Francisco, 1990). 
     7. Wilkinson and Barnes, “The dihydropyridine-sensitive calcium channel subtype in cone photoreceptors”,  J. Gen. Physiol.  107, 621-630 (1996). 
     8. Boycott, et al., “A 2-megabase physical contig incorporating 43 DNA markers on the human X chromosome at p11.23-p11.22 from ZNF21 to DXS255 ”, Genomics  33, 488-497 (1996). 
     9. Schindelhauer, et al., “Long-range mapping of a 3.5-MB region in Xp11.23-22 with a sequence-ready map from a 1.1-Mb gene-rich interval”,  Genome Res  6. 1056-1069 (1996). 
     10. Boycott, et al., “Construction of a 1.5 Mb bacterial artificial chromosome (BAC) contig in Xp11.23, a region of high gene content”  Genomics,  48:369-372 (1998). 
     11. Fisher, et al., “Sequence-based exon prediction around the synaptophysin locus reveals a gene-rich area containing novel genes in human proximal Xp”.  Genomics  45, 340-347 (1997). 
     12. Williams, et al., “Structure and functional expression of a α1, α2, and β subunits of a novel human neuronal calcium channel subtype”,  Neuron  8, 71-84 (1992). 
     13. Schuster, et al., “The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamine”,  EMBO J.  15.2365-2370 (1996). 
     14. Boycott, et al., “Integration of 101 DNA markers across human Xp11 using a panel of somatic cell hybrids”,  Cell Cytogenet. Genet.  76. 223-228 (1997). 
     15. Nathans and Hogness, “Isolation, sequence analysis, and intron-exon arrangement of the gene encoding bovine rhodopsin”,  Cell  34, 807-814 (1983). 
     16. Bech-Hansen, et al., “Loss-of-function mutations in a calcium-channel α 1 -subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness”,  Nature Genet.  19: 264-267 (1998). 
     BACKGROUND 
     X-linked congenital stationary night blindness (CSNB) is a non-progressive retinal disorder characterized by night blindness, decreased visual acuity, myopia, nystagmus and strabismus [1]. Two distinct clinical entities of CSNB have been proposed, complete and incomplete CSNB [2]. In patients with complete CSNB, rod function is not detectable, whereas patients with incomplete CSNB have reduced, but not extinguished rod function. Furthermore, patients with complete CSNB may show moderate to severe myopia, whereas those with incomplete CSNB may show severe myopia to hyperopia [1]. A related disorder, Aaland Island eye disease (AIED), is suggested to be clinically indistinguishable from incomplete CSNB [3]. 
     The biochemical defects underlying complete and incomplete CSNB are not known, but may be revealed by identifying the genes involved in these disorders. The CSNB gene(s) has been localized to the short arm of the human X-chromosome to region p11 by linkage analysis. However, it was uncertain whether the phenotypic variation results from genetic heterogeneity or a single locus exhibiting a wide variation in clinical phenotype [4]. Studies of three families with AIED have localized the AIED gene between DXS7 DXS255, overlapping with the chromosomal region harbouring the gene for incomplete CSNB. 
     Calcium channels are membrane-spanning hetero-oligomeric protein complexes, consisting of (alpha) 1 , (alpha) 2 , (beta) 1 , (beta) 2 , delta and gamma subunits [5], that allow controlled entry of Ca 2+  ions into the cytoplasm from the extracellular space or from intracellular stores. All cells throughout the animal kingdom and some plant, bacteria and fungal cells possess one or more types of calcium channel, which play a central role in the regulation of intracellular Ca 2+  concentration. Changes in intracellular Ca 2+  concentration are implicated in a number of vital processes, such as neurotransmitter release, muscle contraction, pacemaker activity and the secretion of hormones and other substances. 
     Voltage-gated calcium channels (types L, N, and P) are located on the plasma membrane of all excitable animal cells, such as neurons and muscle cells. L-type voltage-gated channels are distinguished pharmacologically from the other types by, among other features, their ability to bind dihydropyridine. 
     The (alpha) 1 -subunits of L-type channels function as the pore and voltage sensors in calcium ion-selective pores [5]. Several diseases are known to be the result of mutations in calcium channel (alpha) 1 -subunit genes, including human familial hemiplegic migraine and episodic ataxia type-2, hypokalemic periodic paralysis, muscular dysgenesis (mdg) and absence epilepsy in tottering mice. Mutations in an L-type calcium channel (alpha) 1 -subunit gene cause myotonia in  C. elegans,  and a non L-type calcium channel (alpha) 1 -subunit gene in Drosophilia (DmcalA) is a suggested candidate gene for the night-blind-A (nbA) and cacophony (cac) mutations. 
     Patients with CSNB, both complete and incomplete, show a reduced b-wave response on electroretinographic testing and decreased dark adaptation. Light-induced hyperpolarization of photoreceptor cells diminishes the release of neurotransmitters at their synaptic terminals, which in turn leads to the depolarization of outer nuclear bipolar and horizontal cells. This depolarization of bipolar cells causes the subsequent depolarization of Mueller cells, which appears largely to be the origin of the corneal positive b-wave [6]. The influx of calcium through dihydropyridine-sensitive calcium channels into photoreceptor cells has been shown to mediate the release of neurotransmitter [7]. Therefore, it is reasonable to presume that one or more L-type voltage-gated channels is involved in neurotransmission in the eye. 
     High-density physical maps of the Xp11.23 cytogenetic region have been constructed in YACs [8], cosmids [9], and BACs [10]. Large scale DNA sequencing in the Xp11.23 region has revealed several new genes. Computer analysis (GRAIL™ and GENE-ID™) of an extended genomic DNA sequence within the Xp11.23 region, has identified potential exons with homology to calcium channel (alpha) 1 -subunit genes [28]. There was an indication that this gene was expressed in skeletal muscle, but this assertion may not be supported by the reported data [28]. The HUGO/GDB Nomenclature Committee has assigned this putative gene the name CACNA1F. The same putative gene was identified by the GENSCAN™, in a computer search of about 1,000 Kb of genomic DNA in this region (Xp11.23) by the Genome Sequencing Centre, Jena. 
     The identification of the gene which is causative of incomplete CSNB may allow for development of diagnostic tests for this disorder and risk assessment in affected families. As well, identification of the gene which is causative of incomplete CSNB will provide information as to the basic defect in this retinal condition, which could lead to effective methods for treatment or cure of the disorder. Furthermore, as the associated features of myopia, nystagmus and strabismus frequently observed in patients with incomplete CSNB may possibly be caused by calcium-regulated developmental pathways, identification of the retinal calcium channel gene may help to elucidate the molecular details of eye development and which may lead to treatment for related eye disorders or diseases. 
     The identification of a calcium channel gene that is expressed in the human retina. will aid in the elucidation of the role of calcium channels in retinal function. Knowledge of the structure of this gene will lead to studies of the structure-function relationships of the protein in the retinal environment. This knowledge, in turn, would be useful in the design and discovery of therapeutic agents whose activities are exerted by interacting directly or indirectly with a calcium channel. 
     Finally, given the diversity and importance of voltage-gated calcium channels in mammalian physiology, possession of cells which express selected channel subtypes would find use in the area of pharmacology and drug design. The identification of novel channel subtypes will expand this area of the medical arts. 
     SUMMARY OF THE INVENTION 
     The region on the short arm of the human X-chromosome, Xp11, which carries the gene for incomplete CSNB (CSNB2) was refined to a distance of 1.2 Mb, between DXS722 and DXS255. 
     A gene, CACNA1F, with homology to voltage-gated L-type calcium channel (alpha) 1 -subunit genes, and that mapped to the CSNB2 minimal region was identified as being retina-specific. The complete cDNA sequence of this gene has been elucidated. Mutational analysis of CACNA1F in 31 families with incomplete CSNB revealed 15 different mutations, predicted to cause premature termination of, or missense mutations in, the protein product of CACNA1F. Together, these findings establish that mutations in CACNA1F cause incomplete CSNB. 
     In addition, mutational analysis of CACNA1F in four families with AIED revealed four different mutations, predicted to cause premature termination of, or missense mutations in, the protein product of CACNA1F. Two mutations were found in both a family diagnosed with incomplete CSNB and another family diagnosed with AIED, suggesting that these two disorders are the same. Therefore, in total, mutational analysis of 35 families with either incomplete CSNB or AIED revealed 17 mutations in the CACNA1F gene. 
     The murine orthologue of the human CACNA1F has been identified and the cDNA sequence determined. There is a high degree of sequence homology between the murine and the human CACNA1F gene, which is as high as 95% in some regions. 
     The present invention provides a mammalian nucleic acid sequence encoding a novel calcium channel (alpha) 1F -subunit expressed in the retina. Thus, in one aspect, this invention is an isolated DNA molecule comprising a sequence of nucleotides that encodes an (alpha) 1F -subunit of a mammalian retinal calcium channel, including a human (alpha) 1F -subunit, a murine (alpha) 1F -subunit and orthologues of the human and murine (alpha) 1F -subunits. 
     In one embodiment, the invention comprises a DNA molecule that encodes a human retinal (alpha) 1F -subunit and has a sequence of nucleotides selected from a group consisting of: 
     (a) the sequence set forth in SEQ ID NO. 1; 
     (b) a sequence of nucleotides that encodes the sequence of amino acids set forth in SEQ ID NO 2; 
     (c) the sequence set forth in SEQ ID NO. 3; or 
     (d) a sequence of nucleotides that encodes the sequence of amino acids set forth in SEQ ID NO 4. 
     In another embodiment, this invention comprises a DNA molecule that encodes a murine (alpha) 1F -subunit and has a sequence of nucleotides selected from a group consisting of: 
     (a) the sequence set forth in SEQ ID NO 5; or 
     (b) a sequence of nucleotides that encodes the sequence of amino acids set forth in SEQ ID NO6. 
     In another aspect, this invention comprises a substantially pure (alpha) 1F -subunit of a mammalian retinal calcium channel, including a human (alpha) 1F -subunit represented by the sequence of amino acids set forth in SEQ ID NO. 2 or 4, a murine (alpha) 1F -subunit represented by the sequence of amino acids set forth in SEQ ID NO. 6, and orthologues of the human and murine (alpha) 1F -subunits. 
     In another aspect, this invention comprises an isolated RNA sequence that encodes an (alpha) 1F -subunit of a mammalian retinal calcium channel or an antisense RNA molecule having a sequence that is complementary to the mRNA encoding an (alpha) 1F -subunit of a mammalian retinal calcium channel. 
     In another aspect, this invention comprises an expression vector, preferably a mammalian expression vector, comprising the nucleotide sequence of an (alpha) 1F -subunit of a mammalian retinal calcium channel. 
     In another aspect, this invention is a cell, preferably a eukaryotic cell, comprising a heterologous DNA comprising a nucleotide sequence of (alpha) 1F -subunit of a mammalian retinal calcium channel. 
     In another aspect, this invention comprises an isolated nucleic acid that encodes a full-length (alpha) 1F -subunit of a mammalian retinal calcium channel, wherein the nucleic acid molecule is fully complementary to nucleic acid which is native to a mammalian retinal cell. 
     In another aspect, the invention comprises a method of diagnosing incomplete CSNB which method includes screening for alterations in the sequence of nucleotides disclosed herein. 
    
    
     BRIEF DESCRIPTION OF THE FIGURES 
     FIG.  1 : Physical map of the minimal genetic region of CSNB2 in Xp11.23. The chromosomal region is indicated by the thick black line. The horizontal double-headed arrow indicates the minimal genetic region established for the CSNB2 gene. Genetic markers are indicated along the chromosome with an asterisk. Genes evaluated as candidates for CSNB2 are indicated along the chromosome (no asterisk). 
     FIG.  2 : PCR primers (SEQ ID NO:29 to SEQ ID NO:50) used to determine the nucleotide sequence of human CACNA1F, by amplifying retina cDNA and sequencing it. 
     FIG.  3 : cDNA expression profile in various human tissues, UPPER PANEL: CACNA1F, a 1060 bp PCR product encompassing most of exons 24-33; LOWER PANEL: ubiquitously expressed EST, JRL4A1, a 281 bp PCR product. 
     FIGS. 4A to  4 D: The nucleotide sequence of a splice variant of human CACNA1F (SEQ ID NO:1). The amino acid sequence of this splice variant is indicated underneath in single letter code. (SEQ ID NO: 2). Short vertical lines show the position of exon boundaries. Predicted transmembrane segments are underlined and identified by domain and segment. 
     FIGS. 5A to  5 D: The nucleotide sequence of a longer splice variant of human CACNA1 F (SEQ ID NO: 3). The amino acid sequence of this splice variant is indicated underneath in single letter code. (SEQ ID NO: 4). Short vertical lines show the position of exon boundaries. Predicted transmembrane segments are underlined. 
     FIGS.  6 A- 6 B: CACNA1F exon specific PCR primers (SEQ ID NO. 5 to SEQ ID NO. 138) that may be used for mutation analysis in humans. 
     FIG.  7 : Mutation analysis of the CACNA1F gene in families with incomplete CSNB. (A) Identification of a frameshift mutation caused by insertion of a C nucleotide at position 2971, in amino acid position 1056, in the splice variant depicted in FIG.  4 . Segregation analysis of this mutation was performed by PCR amplification of genomic DNA and resolution of radioactively labelled PCR products by PAGE. Affected individuals and carriers have a 208 bp product while unaffected individuals have a 207 bp product. (B) Identification of a nonsense mutation caused by a G to A transition, which changes a Trp codon to a stop codon at amino acid position 1451 in exon 37, of the splice variant depicted in FIG.  5 . Segregation analysis of this mutation was performed by PCR amplification of exon 37, restriction endonuclease digestion with AvaII and gel electrophoresis of the products. The G to A transition destroys the AvaII site, therefore in affected individuals and carriers the 339 bp PCR fragment is not digested with AvaII, whereas in normal individuals and carriers it is digested into 231 and 108 bp fragments. 
     FIG.  8 —Summary of the 17 mutations of CACNA1F detected in 35 families with incomplete CSNB or AIED. NS. nonsense; Del, deletion; Ins, insertion; MS, missense, simple or complex; LOF, loss of function; SS, splice site; AS, acceptor site; DS donor site. The numbers indicate the position of the mutation in the splice variant represented in SEQ ID NO: 3. Families diagnosed with AIED are indicated with an “e”. 
     FIGS. 9A to  9 F: The nucleotide sequence of murine CACNA1F (SEQ ID NO:5). 
     FIGS. 10A to  10 B: The amino acid sequence of murine CACNA1F (SEQ ID NO: 6). 
     FIGS. 11A to  11 H: Comparison of the nucleotide sequence of human and murine CACNA1F. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The details of the preferred embodiments of the present invention are set forth in the accompanying drawings and description below. Based on the details of the invention described herein, numerous additional innovations and changes will become obvious to one skilled in art. 
     A. Definitions 
     Unless otherwise indicated, all terms used herein have the same meaning as is commonly understood by one skilled in the art of the present invention. Practitioners are particularly directed to  Current Protocols in Molecular Biology  (Ausubel) for terms of the art. 
     As used herein the following terms have the following meanings: 
     “(alpha) 1F -subunit” refers to a protein with an amino acid sequence equivalent to that depicted in FIGS. 4,  5  or  10 , or in SEQ ID NOs. 2, 4 or 6 and includes a protein that is fully functional; a protein that has minor changes in amino acid sequence, such as conservative amino acid substitutions that do not affect activity; a protein resulting from the translation of a splice variant, and a protein that has a minor change in amino acid sequence which affects the function of the protein. Of particular importance, “(alpha) 1F -subunit” includes a protein which contains an amino acid change that is identified in the mutational analysis and which results in incomplete CSNB or a similar disorder designated by another name. 
     “CACNA1F” unless indicated otherwise, “CACNA1F” refers to human CACNA1F, murine CACNA1F or an orthologue thereof. The term “CSNB2” may also refer to CACNA1F, in the appropriate context. 
     “carrier” refers to a female who does not have the phenotype associated with incomplete CSNB, but one of whose copies of the gene causing incomplete CSNB has a mutation in it that may cause incomplete CSNB. 
     “DNA or RNA encoding an (alpha) 1F -subunit” includes any DNA or RNA which would encode a protein that is an “(alpha) 1F -subunit” as defined above. 
     “expression” refers to transcription of a DNA sequence into RNA, and includes transcription which would result in an antisense RNA. Expression also refers to translation of a RNA sequence into a protein. 
     “expression vector” refers to a recombinant DNA construct that comprises, among other elements, a DNA sequence of which expression is desired. An “expression vector” is used to introduce heterologous DNA into cells for expression of the heterologous DNA, as either an episomal element, or after incorporation into the cellular genome. An “expression vector” will contain all of the elements necessary for transcription of the DNA sequence functionally linked to the DNA sequence, including but not limited to, a transcription initiation element, a transcription termination element and elements that modulate expression of the DNA sequence, such as promoters or enhancers. These elements may be native to the DNA sequence of which expression is desired. An expression vector may contain elements that will regulate translation if translation of the resultant RNA transcript into a protein product is desired. 
     “functional” with respect to an (alpha) 1F -subunit of a retinal calcium channel refers to the ability of an (alpha) 1F -subunit of a retinal calcium channel, or a calcium channel comprising an (alpha) 1F -subunit, to provide for and regulate passage of calcium channel selective ions (e.g. Ca 2++  or Ba 2++ ). A fully functional (alpha) 1F -subunit of a retinal calcium channel refers to an (alpha) 1F -subunit of a retinal calcium channel, or a calcium channel comprising an (alpha) 1F -subunit which is able to provide for and regulate entry of calcium channel selective ions at the level of a wild type (alpha) 1F -subunit of a retinal calcium channel. 
     “heterologous” refers to DNA or RNA that does not occur naturally as part of the genome in which it is present, which is found in a location or locations in the genome that differ from that in which it occurs in nature, or which is present in the genome as a result of human manipulation of the genome. It is DNA or RNA that is not endogenous to the cell in which it is found, or that is endogenous to the cell but which has been manipulated in vitro, and has been artificially introduced into the cell. Heterologous DNA or RNA need not be incorporated into the host cell genome, but may be maintained episomally Examples of heterologous DNA include, but are not limited to, DNA that encodes a calcium channel (alpha) 1F -subunit and DNA that encodes RNA or proteins that mediate or alter expression of endogenous DNA by affecting transcription, translation or other regulatable biochemical processes. 
     “high stringency” or “conditions of high stringency” means washing at low salt concentration, less than about 0.2 and preferably about 0.1 SSPE, and at high temperature, more than about 60° C. and preferably about 65° C. It will be understood that an equivalent stringency may be achieved by using alternative buffers, salts and temperatures. 
     “incomplete CSNB” includes eye disorders such as AIED or AIED-like disorders, which are not clinically diagnosed as incomplete CSNB, but which are known or found to be caused by mutation in the CACNA1F coding region. 
     “orthologue” refers to a gene from another mammalian species that is that species&#39; equivalent to the nucleotide sequence presented in SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO: 5. 
     “precursor” refers to a protein with the amino acid sequence corresponding to the sequence of the full length mRNA which, upon translation, results in a protein which may be further processed to form the (alpha) 1F -subunit of a retinal calcium channel. 
     “splice variant” refers to a variant produced by differential processing of a primary transcript of genomic DNA that results in more than one type of mRNA. Splice variants may occur within or between tissue types. Thus, cDNA clones that encode proteins with different amino acid sequences are “splice variants”. 
     “substantially pure” refers to a subunit, protein or polypeptide that is sufficiently free of other polypeptide contaminants to be considered homogeneous by SDS-PAGE or to be unambiguously sequenced. 
     B. Mapping the Location of the Gene for Incomplete CSNB 
     32 families with CSNB, 11 with complete and 21 with incomplete CSNB, were characterized to identify recombination events that would refine the location of the disease gene(s). The methodology used to localize genes on human chromosomes using these and other techniques is well known to those skilled in the art. 
     Critical recombination events in the set of families with complete CSNB localized the disease gene to the region between DXS556 and DXS8083 in Xp11.4-p11.3. Critical recombination events in the set of families with incomplete CSNB localized the disease gene to the region between DXS722 and DXS8023 in Xp11.23 [4] (FIG.  1 ). FIG. 1 also indicates, as overlapping bars that lie underneath the minimal region, the name and approximate position of the BAC&#39;s that encompass the entire minimal region. 
     Further analysis of the families with incomplete CSNB by disease-associated haplotype construction identified 17 families of apparent Mennonite ancestry who share portions of an ancestral chromosome which refined the location of the gene for incomplete CSNB to the region between DXS722 and DXS255, a distance of approximately 1.2 Mb (FIG.  1 ). 
     C. Characterization of the Gene Encoding CACNA1F 
     Candidates for the CSNB2 gene were expected to be expressed in the retina and located in the CSNB2 minimal region (see FIG.  1 ). Five genes (KAT1, SYP1, HB2E, JM4, and JM9) that met these criteria were screened, but no mutations of these genes were found in affected males from the incomplete CSNB families studied. 
     The expression pattern of the putative gene, CACNA1F, with homology to (alpha) 1 -subunits of calcium channels was analysed. Nine man tissue-specific cDNA libraries (QUICK-Screen™ Human cDNA Library Panel, Clonetech) were analyzed by PCR, using primer pairs from exons 24 and 33 (FIG.  2 ). PCR products were electrophoresed on an agarose gel and visualized by ethidium bromide staining. The 1,060 bp PCR product was detected only in the retinal cDNA library (FIG. 3 a ). In contrast, the ubiquitously expressed EST (expressed sequence tag) JRL4A1, amplified by primers For-TTTCTCTCTGTCTACCTTGT (SEQ ID NO: 7) and Rev-CTGCGGGCTCCCTTACTACTG (SEQ ID NO: 8), was detected in all of the cDNA libraries as a 281 bp fragment (FIG. 3 b ). These results demonstrated that CACNA1F is expressed in the retina, and suggest that its expression in other tissues is unlikely. 
     Computer predictions as to where the introns and exons of this gene lie allowed for the design of oligonucleotides that would function as PCR primers for use with cDNA. Primers were designed by using the Primer3™ program. A list of preferred oligonucleotide PCR primers suitable for such a purpose is provided in FIG.  2 . 
     Total human retinal RNA was transcribed into cDNA, which was then subjected to PCR analysis using the above mentioned primers. After amplification, PCR products were prepared for sequencing by agarose gel electrophoresis and purification with Qiaquick™ (Quiagen). Sequencing reactions were performed with Thermosequenase ™ and products were visualised by autoradiography after polyacrylamide gel electrophoresis. These methods are well known to those skilled in the art. 
     The PCR and sequencing analysis described above demonstrated that CACNA1F consists of 48 exons and encodes splice variants, one of which is a protein of 1912 amino acids (FIG.  4 ). Several other splice variant forms were identified by PCR analysis. Therefore, isoforms of varying amino acid lengths are expected. Alternative splicing is a feature commonly seen in the calcium channel (alpha) 1 -subunit genes as a mechanism for forming distinct channels [5] and may be the basis for cell-specific (alpha) 1 -subunit expression. 
     (Alpha) 1 -subunits of L-type calcium channels are pore-forming proteins with cytoplasmic amino and carboxyl termini separated by four homologous domains (I-IV), each consisting of six transmembrane segments (S1-S6). CACNA1F shares these features of calcium channel (alpha) 1 -subunits of L-type channels (see FIGS.  4  and  5 ). CACNA1F is most similar to the L-type C, D and S members of the voltage-gated calcium channel (alpha) 1 -subunit gene family. In particular, CACNA1F appears to have diverged most recently from the human (alpha) 1D -subunit gene (CACNA1D), which is expressed in the brain [16]. The similarity between the human (alpha) 1D -subunit gene and CACNA1F was 70% overall and 84% between transmembrane segments. Of the five amino acids in the IVS6 transmembrane domain that are critical for conferring dihydropyridine sensitivity, four are present in the predicted CACNA1F amino acid sequences, depicted in FIGS. 4 and 5, and identified as SEQ ID NO.&#39;s: 2 and 4. 
     It is understood that the amino acid sequences of CACNA1F disclosed herein may be modified by making minor variations in sequence, such as conservative amino acid substitutions or minor deletions or insertions that do not alter the activity of the subunit, and the resulting modified subunits are contemplated herein. Suitable conservative substitutions of amino acids are known to those of skill in this art, and may be made generally without altering the biological activity of the resulting molecule. Such substitutions may also be made empirically. 
     D. Mutation and Segregation Analysis of the Coding Region of CACNA1F 
     To identify which mutations in CACNA1F cause incomplete CSNB, exons of the CACNA1F gene in patients with incomplete CSNB were analyzed by direct DNA sequencing using intron-based exon-specific PCR primer pairs. In this type of analysis, PCR primers that will bind with intron sequences on either side of the exon(s) of interest are designed. Primers are ideally positioned 20-50 bp from the splice site, and will amplify one or more exons. All primer pairs were confirmed to be region-specific by PCR amplification of a panel of conventional and radiation-induced somatic cell hybrids, as described in [14]. Primers suitable for such a purpose were designed by using the Primer3™ program and are provided in FIG.  6 . After exon(s) in genomic DNA are amplified by the intron-specific primers, the DNA is purified and sequenced, as described in section B above, for the CACNA1F gene analysis. All of these methods are well known to those skilled in the art. 
     Once a nucleotide change is identified by the sequencing analysis, segregation analysis may be accomplished by allele sizing as described in [14] and demonstrated in FIG. 7 a.  PCR is used to amplify the region of interest from genomic DNA of affected, non-affected and carrier individuals. The radioactively-labelled PCR products are electrophoresed through polyacrylamide gels which can distinguish between as little as a single base pair insertion or deletion. 
     Alternatively, segregation analysis may be accomplished by following the loss or gain of restriction sites, as demonstrated in FIG. 7 b.  Mutated and wild-type sequences are compared by a DNA analysis program, for example DNA Strider1.2™, looking for changes in sequence that would result in a loss or gain of a restriction site. Once found, these changes can be used to track the mutation in families of affected individuals. Firstly, PCR is used to amplify the interest from genomic DNA of affected, non-affected and carrier individuals. The PCR products are digested with the enzyme that will detect the mutation (in either a positive or negative sense). The digested products are electrophoresed through agarose and visualized to determine whether the restriction enzyme site is present or not, whichever the case may be, in the individual analysed. 
     Numerous additional methods for identifying mutations of the CACNA1F coding region in individuals, or tracing mutations of the CACNA1F gene through families, including but not limited to SSC and heteroduplex analysis, are obvious to one skilled in the art. 
     In the present invention, 31 families with incomplete CSNB were studied. Of these families, 17 shared part of a common Mennonite haplotype (families 21, 50, 70, 60, 60B, 80, 130, 150, 160, 170, 180, 190, 200, 240, 250, 330, and 340), and three did not (families 100, 140, and 520). Using intron-based exon-specific PCR primer pairs (FIG.  6 ), a total of 17 sequence changes were discovered in all families analyzed (FIG.  8 ), all of which segregated in their respective families to affected males, through carrier females. None of these were observed in 100 control chromosomes, indicating that these sequence changes are not polymorphic alterations of CACNA1F in the Caucasian population. However, there were several additional mutations detected in the CACNA1F gene which were determined to represent polymorphisms in the Caucasian population. 
     As well, four families with AIED were studied. Using intron-based exon-specific PCR primer pairs, a total of four sequence changes were discovered in the CACNA1F gene in these families (FIG. 8) (all of which segregated in their respective families to affected males, through carrier females). None were observed in 100 control chromosomes, indicating that these sequence changes are not polymorphic alterations of CACNA1F in the Caucasian population. 
     Fifteen families with common Mennonite haplotype were found to segregate the same frameshift mutation in CACNA1F, called L1056insC (FIG. 7 a,  FIG.  8 ). Segregation analysis of this mutation was performed by allele sizing of exon 27, as demonstrated in FIG. 7 a.  In one of these families (family 60), three females who manifest with incomplete CSNB and who were previously suggested by haplotype analysis to be homozygous for the “Mennonite” mutation showed only the L1056insC mutation and no normal allele (FIG. 7 a ). The other two families which previously were found to have the common Mennonite haplotype (families 21 and 70) showed different frameshift mutations (I1224delC and D406delC, respectively) (FIG.  8 ). In other families with incomplete CSNB (families 100, 140, and 520), unique nonsense mutations in CACNA1F were seen (R1299X; W1451X, and R895X, respectively) (FIG.  8 ). Two loss of function mutations are caused by different mutations in splice acceptor sites (Exon27AS and Exon41AS, FIG.  8 ). 
     In addition, six missense mutations in CACNA1F, each of which cause incomplete CSNB or AIED, have been detected. Missense mutations, which are only a minor variation in the sequence of a protein, yet which cause these disorders, are presumed to represent amino acids that have a very important role in the function of the CACNA1F protein. 
     Our identification of 11 different mutations of CACNA1F in families with incomplete CSNB or AIED, which would cause premature stop codons and therefore truncated translation products, strongly argues that mutations in CACNA1F cause these disorders. Further, the occurrence of the L1056insC mutation in fifteen families with the common Mennonite haplotype supports the suggestion that these families are related by a founder mutation. Consequently, it is likely that the L1056insC “Mennonite” mutation will be observed in other descendants of Mennonite immigrants who came to Western Canada in the last century, and among descendants of their Russian and European forefathers in other parts of the world. Of note, families 21 and 70 that share part of the Mennonite haplotype show different frameshift mutations. 
     E. Possible Consequences of CACNA1F Mutations 
     The 17 mutations identified in our 35 families with incomplete CSNB or AIED are distributed across CACNA1F coding region. Mutations that would result in a truncated protein are predicted to result in a loss of function. Additional characterization of the truncated proteins may reveal the specific consequences of each mutation. 
     Missense mutations are predicted to disrupt specific functions of the intact CACNA1F and therefore are much more informative as to the structure-function relationship of intact CACNA1F in the calcium channel. 
     F. Construction of Full-Length cDNA Clones 
     Full length cDNA clones may be constructed by a plurality of methods known to those skilled in the art. Such methods include screening a cDNA library with a labeled DNA probe of the gene of interest, identifying overlapping cDNA clones and ligating them together into one clone that contains the entire coding region. One may also obtain a full length cDNA clone in one step from a library, obviating the need to perform intermediary ligation steps. If the 5′ or 3′ end only of the clone is missing, methods such as RACE (rapid amplification of cDNA ends) may be used to complete the sequence, or if the full length sequence is known, PCR amplification and ligation of the fragments onto the ends of the cDNA clone may be used. 
     Alternatively, in another well-known method, one may use PCR to amplify regions of a gene of interest from a cDNA library or a cDNA preparation, and subsequently ligate the PCR products together into one clone that contains the entire coding region. Using this method, one skilled in the art may select from a variety of cloning vectors, including high and low copy number plasmids, such as pBluescript or pBR322 or phage and one may also select from a variety of bacterial hosts. Rather than ligating smaller PCR fragments together, it is also possible to PCR an entire cDNA sequence using a Taq Polymerase that is designed for long range PCR, such as pfu™ or Vent™ Polymerase, and then ligate that entire fragment into a suitable vector. 
     For ligation of PCR fragments together to create a full length cDNA clone, primer sets are designed to yield overlapping PCR fragments of manageable size, which will, when combined, represent the entire full-length cDNA. The primers are also designed such that the PCR fragments which are amplified will contain restriction sites that are unique to the cDNA and the vector in which the fragment is to be inserted. A preferred vector is PCR2.1-TOPO™ (Invitrogen). The forward primer for the most 5′ fragment is designed to contain a small ribosomal binding site. The forward primer for the most 5′ fragment and the reverse primer for the most 3′ fragment (the extreme 5′ and 3′ ends, respectively) also contain recognition sites for extremely rare cutting restriction endonucleases, such as NotI. 
     First strand cDNA can be amplified with or without DNA polymerase of high fidelity such as Turbo Pfu™ (Strategene). PCR products are verified by DNA sequencing and restriction digestion, to ensure that they are identical in sequence to the native cDNA. Fragments are then ligated together into one complete transcription unit and again checked for accuracy by restriction analysis. A person skilled in the art may modify these methods as necessary, depending upon the exigencies presented in each particular step of the assembly. 
     G. Preparation of Cells Containing a Recombinant DNA Encoding an (Alpha) 1F -subunit 
     DNA encoding an (alpha) 1F -subunit, or a portion thereof, may be introduced into a host cell for expression of the DNA using methods well known to those skilled in the art. Such methods include for example, preparation of a suitable expression vector, introduction of the expression vector into suitable cells and selection of transfected cells. 
     Practice of the present invention can be effectively carried out using any of a number of expression vectors. A person skilled in the art may choose the vector that is appropriate, depending upon, among other factors, the cell type and the type of expression desired. For instance, vectors include, but are not limited to, those that constitutively express a DNA sequence at high or low levels, or those that inducibly express a DNA sequence at high or low levels. Particularly preferred vectors for transfection of mammalian cells are pSV2dhfr expression vectors, and for prokaryotic cells, pBluescript™ vectors (Stratagene) or pBR322 vectors. 
     Practice of the present invention can be effectively carried out using any of a number of different cell types, eukaryotic or prokaryotic. A person skilled in the art will choose the cell line that is appropriate, depending upon the desired application. For example, if a large amount of substantially pure protein product is desired, a prokaryotic or yeast cell may be selected. If functional calcium channel activity is the desired objective, a mammalian cell may be selected, and depending upon the desired application, the mammalian cell may lack endogenous calcium channel activity, or may contain additional different expression vectors that encode other components of a calcium channel. One skilled in the art may choose an expression vector that will either integrate, or not integrate, into the chromosomal DNA of the cell. Preferred mammalian cells include COS cells. CHO cells, HEK cells or mouse L cells. Preferred prokaryotic cells include strains of  Escherichia coli  such as DH1α or JM109. Yeast cells such as  Saccaharomyces cerevisiae  may also be utilized. 
     Introduction of the expression vector into cells may be accomplished by transfection, using techniques that include calcium phosphate precipitation, electroporation or injection. A person skilled in the art will choose the method that is appropriate. The preferred method of transfecting DNA is by electroporation. The method of selection for transfected cells will depend upon the selectable marker chosen, and may include the gene for thymidine kinase or neomycin resistance in mammalian cells, and ampicillin or kanamycin resistance in prokaryotic cells. 
     Mammalian expression systems are particularly preferred for practicing certain aspects of this invention. 
     It is also within the contemplation of this embodiment that recombinant cells containing DNA encoding an (alpha) 1F -subunit may be prepared by means that do not include the use of an expression vector. This would be the case for instance, if the preparation of the recombinant cell containing DNA encoding an (alpha) 1F -subunit was for the purpose of replication of the DNA sequences themselves, as might occur if the DNA to be used in section I, below or if the DNA was to be used in intermediate steps of in vitro gene manipulation. 
     It is also within the contemplation of this embodiment that cells containing a recombinant expression vector comprising a gene for an (alpha) 1F -subunit may be prepared for the purpose of expressing an antisense RNA transcript of CACNA1F or a part thereof within the cell. To accomplish this, the CACNA1F insert may be ligated into the expression vector in reverse orientation, such that transcription from a promoter will result in an RNA transcript that is complementary to the mRNA in the cell. 
     In another embodiment, vectors that are designed to allow for integration of the DNA sequence into the genome of an organism, rather than expression of the DNA sequence, may be used to introduce the DNA sequence into the recombinant cell. Such vectors would include, for instance, phage vectors that are used in transgenic mouse technology. 
     H. Preparation of Cells Containing the Protein Product of CACNA1F 
     In most instances, the cells prepared intra section H, above, will be designed to express the protein product of CACNA1F, an (alpha) 1F -subunit. This would occur via transcription of the heterologous CACNA1F sequences after introduction into the cell. 
     It may be desired to express an (alpha) 1F -subunit in a cell without utilizing the intervening steps of introducing the DNA encoding an (alpha) 1F -subunit into the cell. A plasmid, such as pBluescript™, containing the DNA encoding an (alpha) 1F -subunit, or a part thereof, may be transcribed in vitro with an RNA polymerases, such as T7 RNA polymerase, to produce an abundant RNA transcript that is easily isolated. This RNA transcript is designed to include the appropriate signals for translation, including translation initiation and termination sites. When injected into cells such as oocytes from  Xenopus laevis,  the RNA is translated into the protein for which it encodes. Additional RNA transcripts, encoding other subunits of calcium channels may also be injected into the same oocyte if it is desired to create functional heterologous calcium channels in the oocyte. 
     Methods for in vitro transcription and injection of the resulting RNA into eukaryotic cells are well known in the art. Amphibian oocytes are particularly preferred for this aspect of the invention. 
     H. Identification of CACNA1F Orthologues in Other Mammalian Species 
     cDNA&#39;s representing several mouse tissues were amplified by PCR with the primers indicated in FIG. 2, used for the human CACNA1F. The amplified PCR fragments were sequenced and compared to the human CACNA1F sequence. 
     Primer sets for exons 6-10, 10-15, 20-28, 24-32 and 35-38 yielded PCR products from murine retina cDNA which were approximately the same size as the human PCR products with the same primer sets. Murine CACNA1F was expected to be highly homologous to the human CACNA1F, therefore the size of the PCR fragment generated in the mouse cDNA was likewise expected to be similar to the human CACNA1F. 
     In other instances, more than one PCR product for a particular primer pair was observed, or the band that was amplified was not the expected size. Where primer pairs would amplify overlapping segments (i.e. 6-10 and 10-15 would both amplify region 10), then sequences of the two PCR fragments were compared and if they were identical, both fragments were presumed to come from the murine CACNA1F gene. If they were not identical, then it was presumed that the PCR fragment with higher homology to human CACNA1F contained murine CACNA1F sequence and the other fragment did not. These strategies yielded more than 1/2 of the murine CACNA1F sequence. 
     To obtain the much of the remainder of the murine CACNA1F sequence, three mouse specific primers sets, covering exons 15-21, 32/33-38 and 38-42 were designed from the mouse sequence that was known at that point. The sequence of these primers is provided in Example 4, below. These primers were used to amplify the additional regions of murine CACNA1F. 
     There was some difficulty amplifying exons 3 to 10 of the murine CACNA1F sequence. To circumvent this, amplification was performed by using a human-specific forward primer and a mouse-specific reverse primer, as shown in Example 4, below. 
     Finally, the 5′ and 3′ ends of the murine cDNA sequence for CACNA1F were obtained by 5′ and 3′ RACE, using the Marathon cDNA Amplification Kit (Clonetech). These methods are well known to those skilled in the art. 
     The murine CACNA1F gene was mapped to chromosome X of the mouse. Further, it is situated adjacent to the Syp gene in mouse, as the human CACNA1F gene is located beside the human SYP gene the X-chromosome. This similarity is additional evidence that these genes are orthologues of one another. 
     It is apparent to persons skilled in the art, that orthologues of CACNA1F may be identified in, and isolated from, other mammalian species using other methods, including screening of genomic or cDNA libraries with a labeled human or murine DNA probe. The examples and preferred embodiments outlined herein do not preclude the use of these other methods. 
     EXAMPLES 
     The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be utilized. 
     Example 1 
     Analysis of Genomic Structure 
     A retinal cDNA library (JNR. [15]) and retinal first strand cDNA from total mRNA, were used as templates for generation of detailed exon sequence of the computer predicted calcium channel (alpha) 1 -subunit. PCR amplification was performed with AmpliTaq Gold™ polymerase (Perkin Elmer) in 1.5 mM MgCl 2  and the supplied buffer. An initial denaturation of 7 min at 94° C., was followed by 35 cycles of: denaturation at 94° C. for 30 s, annealing at 55° C. for 45 s. and extension at 72° C. for 45 s, followed by final extension for 7 min at 72° C. PCR products were isolated in 1% low melting point agarose gel and purified using a QIAquick™ gel extraction kit (Qiagen). Purified PCR fragments were then sequenced using the forward and/or reverse primer and ThermoSequenase™ radiolabeled terminator cycle sequencing (Amersham LIFE SCIENCE), electrophoresed on 6% polyacrylamide gels, and visualized by autoradiography. 
     Example 2 
     Mutation Analysis 
     Genomic DNA (300 ng) was amplified with AmpliTaq Gold™ polymerase (Perkin Elmer), in 1.5 mM MgCl 2  for all exons, with the exception of exons 13, 14 and 30, which were amplified in 1.0 mM MgCl 2 , and exon 43, which was amplified in 0.5 mM MgCl 2 . Cycling conditions were the same as used for the confirmation of exon/intron structure, described above. Purified PCR products from affected and control individuals were sequenced using ThermoSequenase™ radiolabeled terminator cycle sequencing (Amersham LIFE SCIENCE), electrophoresed on 6% polyacrylamide gels, and visualized by autoradiography. 
     Example 3 
     Segregation Analysis 
     Once a nucleotide change was identified, the loss or gain of restriction sites of the PCR fragment was analyzed using DNA Strider 1.2™. For example, the nucleotide change in exon 9 resulted in a gain of a FokI site (Normal (N)-271 bp; Mutant (M)-136 bp, 134 bp); in exon 21 the loss of a FokI site (N-94 bp, 77 bp, 42 bp, 36 bp, M-113 bp, 94 bp, 42 bp); in exon 30 the loss of a FokI site (N-159 bp, 132 bp, 2 bp; M-290 bp, 2 bp); in exon33 the gain of a DdeI site (N-108 bp, 68 bp, 41 bp, 35bp, 22bp, 10 bp; M-108 bp, 43 bp, 41 bp, 35 bp, 25 bp, 22 bp, 10 bp), and in exon 37 the loss of an AvaII site (N-231 bp, 108 bp; M-339 bp). Segregation analysis was performed using all available family members. Genomic DNA samples were amplified by PCR, as described above and cut with the appropriate restriction enzyme (FIG.  7 ). The products were separated on 2% SEPARIDE/1% agarose gels and visualized by ethidium bromide staining. Segregation analysis for the one base insertion in exon 27 was based on separation of radioactively labelled PCR products (N-207 bp; M-208 bp) in 6% polyacrylamide gels. Routinely, a minimum of 100 random Caucasian control chromosomes were also evaluated for the presence of each of the nucleotide changes by the methodology described for the segregation analyses. 
     Example 4 
     Identification and Isolation of the Sequence of the Murine CACNA1F Orthologue 
     Murine eye mRNA was reverse-transcribed and PCR, isolation of fragments and sequencing of the DNA was carried out as described above in Example 1. Primer sets for exons 6-10, 10-15, 20-28, 24-32 and 35-38 (FIG. 2) yielded PCR products from murine retina cDNA which upon sequencing were determined to contain murine CACNA1F sequence. Mouse specific primers sets, whose products would cover exons 15-21, 32-38 and 38-42 were designed as follows: 
     
       
         
               
               
               
             
           
               
                 TABLE 1 
               
               
                   
               
               
                 Exons Amplified 
                 Forward Primer 
                 Reverse Primer 
               
               
                   
               
             
             
               
                 15-21 
                 atctggtggcatctttgctc 
                 agcagccagggacacactac 
               
               
                   
                 (SEQ ID NO: 9) 
                 (SEQ ID NO: 10) 
               
               
                 32/33-38 
                 ggcgagagttcagaggacag 
                 ccacatccaagtgttgatgc 
               
               
                   
                 (SEQ ID NO: 11) 
                 (SEQ ID NO: 12) 
               
               
                 38-42 
                 ggatcaagccaaccagga 
                 ctttggttcccttgggct 
               
               
                   
                 (SEQ ID NO: 13) 
                 (SEQ ID NO: 14) 
               
               
                 40N-48N 
                 ttccggagaaggaaagaaaa 
                 cacaaatcgtgggtcttgg 
               
               
                   
                 (SEQ ID NO: 15) 
                 (SEQ ID NO: 16) 
               
               
                   
               
             
          
         
       
     
     Sequencing was performed with the primers that were used to amplify the PCR products. When sequencing did not cover the entire PCR product, new mouse-specific primers were designed as follows: 
     
       
         
               
               
             
           
               
                 TABLE 2 
               
               
                   
               
               
                 Primer Name 
                 Primer Sequence 
               
               
                   
               
             
             
               
                 mJM8Ex20F2 
                 actcaagatgacagtgtttg (SEQ ID NO: 17) 
               
               
                 mJM8Ex28R2 
                 cctggtttccagcactgtgt (SEQ ID NO: 18) 
               
               
                 mJMC8Ex6-10(F2) 
                 actgaaccataccgagtgcc (SEQ ID NO: 19) 
               
               
                 mJMC8Ex6-10(R2) 
                 tcagcctgtgtgatccagtc (SEQ ID NO: 20) 
               
               
                 mJMC8Ex10-15(F2) 
                 atgaaaacaaggatctgccg (SEQ ID NO: 21) 
               
               
                 mJMC8Ex10-15(R2) 
                 gagacgtacacatcggagca (SEQ ID NO: 22) 
               
               
                 mJMC8Ex38mJMC8Ex38-46F3 
                 cacctcactggtcagca (SEQ ID NO: 23) 
               
               
                   
               
             
          
         
       
     
     The methods above yielded all but the 5′ and 3′ sequences of the murine CACNA1F gene. To determine these sequences, 5′ and 3′ rapid amplification of cDNA Ends (RACE) was performed using the Marathon™ cDNA Amplification kit (Clontech). Total RNA was extracted from mouse eyes, and polyA +  RNA was isolated. Double stranded cDNA was synthesized, blunt ended and the Marathon™ Adaptor was ligated to the ends of the cDNA. 
     Primers were designed according to the specifications outlined in the CLONTECH manual for touchdown PCR. Two sets of primers, specific to the 5′ and 3′ ends of the murine CACNA1F gene, were used. These sets included a primer that lay closer to each end of the cDNA for nested amplification: 
     
       
         
               
               
               
             
           
               
                 TABLE 3 
               
               
                   
               
               
                 End of cDNA 
                 First gene specific primer 
                 Nested gene specific primer 
               
               
                   
               
             
             
               
                 5′ end 
                 catggcatcctgcatccagtagagg 
                 gtccgaggaatagctcgagtccgatg 
               
               
                   
                 (SEQ ID NO: 24) 
                 (SEQ ID NO: 25) 
               
               
                 3″ end 
                 ctcccaaccacacaggagaagctctg 
                 cccctgttgttggtggaggaatctac 
               
               
                   
                 (SEQ ID NO: 26) 
                 (SEQ ID NO: 27) 
               
               
                   
               
             
          
         
       
     
     
       
         
           
             138 
           
           
             1 
             5813 
             DNA 
             Homo sapiens 
           
            1
atgtcggaat ctgaaggcgg gaaaggtgag agaatccttc catccctgca gacccttgga     60
gcaagcatcg tggagtggaa gcccttcgac atcctcatcc tgctgaccat ctttgccaac    120
tgcgtggccc tgggagttta catccccttc cctgaggacg actccaacac tgccaaccac    180
aacctggagc aggtggagta cgtattcctg gtgattttca ctgtggagac ggtgctcaag    240
atcgtggcct acgggctggt gctccacccc agcgcctaca tccgcaatgg ctggaaccta    300
ctcgacttca tcatcgtcgt ggtcgggctg ttcagcgttc tgctggagca gggccccgga    360
cggccaggcg acgccccgca caccggggga aagccaggag gcttcgatgt gaaggcattg    420
agggcgtttc gggtgctgcg gccactgagg ctggtgtctg gggtcccgag cctgcacata    480
gtgctcaatt ccatcatgaa ggctctggtg ccgctgctgc acattgcact gctcgtgctc    540
ttcgtcatca tcatttatgc catcattggg ctcgagctgt tccttggacg aatgcacaag    600
acgtgctact tcctgggatc cgacatggaa gcggaggagg acccatcgcc ctgtgcgtct    660
tcgggatcag ggcgtgcgtg cacgctgaac cagactgagt gccgcgggcg ctggccaggg    720
cccaatggag gcatcaccaa ctttgacaac ttcttcttcg ccatgctgac agtcttccag    780
tgtgtcacca tggaaggctg gaccgatgtg ctctactgga tgcaagatgc catggggtat    840
gaactgccct gggtgtactt tgtgagcctt gtcatctttg ggtccttctt cgtcctcaac    900
cttgtgcttg gcgtcctgag tggggagttc tccaaggaga gagagaaagc gaaagctcgc    960
ggggacttcc agaagcagcg ggagaagcag cagatggagg aagacctgcg gggctacctg   1020
gactggatca ctcaagccga agagctggac atggaggacc cctccgccga tgacaacctt   1080
ggttctatgg ctgaagaggg ccgggcgggc catcggccac agctggccga gctgaccaat   1140
aggaggcgtg gacgtctgcg ctggttcagt cattctactc gctccacaca ctccaccagc   1200
agccatgcca gcctcccagc cagtgacacc ggttccatga cagagaccca aggcgatgag   1260
gatgaggagg agggggctct ggccagctgt acacgctgcc taaacaagat catgaaaacc   1320
agagtctgcc gccgcctccg ccgagccaac cgggtccttc gggcacgctg ccgtcgggca   1380
gtgaagtcca atgcctgcta ctgggctgtg ctgttgctcg tcttcctcaa cacgttgacc   1440
atcgcctctg agcaccacgg gcagcctgtg tggctcaccc agatccagga gtatgccaac   1500
aaagtgttgc tctgtctgtt cacggtggag atgcttctca aattgtacgg tctgggcccc   1560
tctgcctatg tgtcttcctt cttcaaccgc tttgactgct ttgtggtctg tgggggcatc   1620
ctagagacca ccttggtgga ggtgggcgcc atgcagccct tgggcatctc agtgctccga   1680
tgtgtgcgcc tcctcaggat ctttaaggtc accagacact gggcttctct gagcaatctg   1740
gtggcatccc tgctcaattc aatgaaatcc atcgcatcct tgctgcttct cctcttcctc   1800
ttcatcatta tcttctccct gcttggcatg cagctgtttg ggggcaagtt caactttgac   1860
cagacccaca ccaagcgaag cacctttgac acgttccccc aggccctcct cactgtcttt   1920
cagatcctga caggtgagga ctggaacgtg gtcatgtatg atggtatcat ggcatatggt   1980
ggccccttct tcccaggaat gttggtgtgc atctatttca tcattctctt catctgtggc   2040
aactacatcc tgttgaacgt gtttcttgcc attgctgtgg acaacctggc cagtggagat   2100
gcaggcactg ccaaggacaa gggcggggag aagagcaatg agaaggatct cccacaggag   2160
aatgaaggcc tggtgcctgg tgtggagaaa gaggaagagg agggtgcaag gagggaagga   2220
gcagacatgg aggaggagga ggaggaggaa gaagaggaag aagaggaaga agaggaagag   2280
ggtgcagggg gtgtggaact cctgcaggaa gttgtaccca aggagaaggt ggtacccatc   2340
cctgagggca gcgccttctt ctgcctcagc caaaccaacc cgctgaggaa gggctgccac   2400
accctcatcc accatcatgt cttcaccaat cttatcctgg tgttcatcat cctcagcagt   2460
gtgtccctgg ccgctgagga ccccatccga gcccactcct tccgcaacca tattctgggt   2520
tacttcgatt atgccttcac ctccattttc actgtggaga ttctactaaa gatgacagtg   2580
tttggggcct tcctgcaccg cggctccttc tgccgtagct ggtttaatat gttggatctg   2640
ctggtggtca gtgtgtccct catctccttt ggcatccact ccagcgccat ctcggtggtg   2700
aagattctgc gagtactccg agtactgcgg cccctccgag ccatcaacag ggccaaggga   2760
ctcaagcatg tggtgcagtg tgtatttgtg gccatccgga ccatcggaaa catcatgatt   2820
gtcaccacac ttctgcaatt tatgttcgcc tgcatcgggg tgcagctctt caaggggaaa   2880
ttctacacct gcacggacga ggccaaacac acccctcaag aatgcaaggg ctccttcctg   2940
gtatacccag atggagacgt gtcacggccc ctggtccggg agcggctctg ggtcaacagt   3000
gatttcaact ttgacaatgt cctttcagcc atgatggccc tgttcactgt ctccaccttt   3060
gaaggctggc ctgcactgct atacaaggcc atcgatgcat atgcagagga ccatggcccc   3120
atctataatt accgtgtgga gatctcagtg ttcttcattg tctacatcat catcattgcg   3180
ttcttcatga tgaacatctt cgtgggcttc gtcatcatca ctttccgtgc ccagggcgag   3240
caggagtacc aaaactgtga gctggacaag aaccagcgtc aatgtgtgga atatgccctc   3300
aaggcccagc cactccgccg ttacatcccc aagaacccgc atcagtatcg tgtgtgggcc   3360
actgtgaact ctgctgcctt tgagtacctg atgttcctgc tcatcctgct caacacagtt   3420
gctagcccca tgcagcacta tgagcagact gctcccttca actatgccat ggacatcctc   3480
aacatggtct tcactggcct cttcactatt gagatggtgc tcaaaatcat cgccttcaag   3540
cccaagcatt acttcactga tgcctggaac acgtttgacg ctcttattgt ggtgggcagc   3600
atagtggata ttgccgtcac tgaagtcaat aatggtggcc accttggcga gagctctgag   3660
gacagctccc gcatttccat taccttcttt cgcctcttcc gagttatgcg gctggtcaag   3720
cttctcagta agggtgaagg gatccgcaca ttgctctgga cattcatcaa gtccttccag   3780
gccttgccct atgtggctct tctcatcgca atgatattct tcatctatgc cgtcattggc   3840
atgcagatgt tcggcaaggt ggctcttcag gatggcacac agataaaccg aaacaacaac   3900
ttccagacct ttccacaggc tgtgctgctt ctgttcaggt gtgccactgg tgaggcatgg   3960
caggagataa tgcttgccag ccttcccgga aatcggtgtg atcctgagtc tgacttcggc   4020
cctggtgaag agtttacctg tggtagcaat tttgccatcg cctatttcat cagcttcttc   4080
atgctctgtg ccttcctgat cataaatctc tttgtggctg tgatcatgga caactttgat   4140
tatctcacca gagattggtc catcctgggc ccccatcacc ttgatgaatt caagaggatc   4200
tggtctgaat atgaccctgg ggccaagggc cgcatcaaac acttggatgt ggttgccctg   4260
ctgagacgta tccagccccc tctgggattt gggaagctgt gcccacaccg agtggcctgc   4320
aagagacttg tggcaatgaa catgcccctc aactcagatg ggacggtgac attcaacgcc   4380
acactctttg ccctggtccg gacatccctg aagatcaaaa cagaagggaa cctggagcaa   4440
gccaaccagg agctgcggat tgtcatcaaa aagatctgga agcggatgaa acagaagctg   4500
ctagatgagg tcatcccccc accagacgag gaggaggtca ccgtgggcaa attctacgcc   4560
acatttctga tccaggacta tttccgcaaa ttccggcgga ggaaagaaaa agggctacta   4620
ggcaacgacg ccgcccctag cacctcttcc gcccttcagg ctggtctgcg gagcctgcag   4680
gacttgggtc ctgagatgcg gcaggccctc acctgtgaca cagaggagga ggaagaagag   4740
gggcaggagg gagtggagga ggaagatgaa aaggacttgg aaactaacaa agccacgatg   4800
gtctcccagc cctcagctcg ccggggctcc gggatttctg tgtctctgcc tgtcggggac   4860
agacttccag attcactctc ctttgggccc agtgatgatg acagggggac tcccacctcc   4920
agtcagccca gtgtgcccca ggctggatcc aacacccaca ggagaggctc tggggctctc   4980
attttcacca tcccagaaga aggaaattct cagcccaagg gaaccaaagg gcaaaacaag   5040
caagatgagg atgaggaagt ccctgatcgg ctttcctacc tagatgagca ggcagggact   5100
cccccgtgct cagtcctttt gccacctcac agagctcaga gatacatgga tgggcacctg   5160
gtaccacgcc gccgtctgct gccccccaca cctgcaggtc ggaagccctc cttcaccatc   5220
cagtgtctgc agcgccaggg cagttgtgag gatttaccca tcccaggcac ctatcatcgt   5280
gggcgaaatt cagggcccaa tagggctcag ggttcctggg caacaccacc tcagcggggt   5340
cggctcctgt atgccccgct gttgttggtg gaagagggcg cagcggggga ggggtacctc   5400
ggcagatcca gtggcccact gcgcaccttc acctgtctgc acgtgcctgg aacccactcg   5460
gaccccagcc atgggaagag gggcagtgcc gacagcttgg tggaggctgt gcttatctca   5520
gagggtctgg gcctctttgc tcgagaccca cgtttcgtgg ccctggccaa gcaggagatt   5580
gcagatgcgt gtcgcctgac gctggatgag atggacaatg ctgccagtga cctgctggca   5640
cagggaacca gctctctcta tagcgacgag gagtccatcc tctcccgctt cgatgaggag   5700
gacttgggag acgagatggc ctgcgtccac gccctctgaa ttcccacccc tccccaactg   5760
ctcaataaac ctcctgccct cccctcccca gcaggaggca ggcatggacc aca          5813
 
           
             2 
             1912 
             PRT 
             Homo sapiens 
           
            2
Met Ser Glu Ser Glu Gly Gly Lys Gly Glu Arg Ile Leu Pro Ser Leu
 1               5                   10                  15
Gln Thr Leu Gly Ala Ser Ile Val Glu Trp Lys Pro Phe Asp Ile Leu
             20                  25                  30
Ile Leu Leu Thr Ile Phe Ala Asn Cys Val Ala Leu Gly Val Tyr Ile
         35                  40                  45
Pro Phe Pro Glu Asp Asp Ser Asn Thr Ala Asn His Asn Leu Glu Gln
     50                  55                  60
Val Glu Tyr Val Phe Leu Val Ile Phe Thr Val Glu Thr Val Leu Lys
65                   70                  75                  80
Ile Val Ala Tyr Gly Leu Val Leu His Pro Ser Ala Tyr Ile Arg Asn
                 85                  90                  95
Gly Trp Asn Leu Leu Asp Phe Ile Ile Val Val Val Gly Leu Phe Ser
            100                 105                 110
Val Leu Leu Glu Gln Gly Pro Gly Arg Pro Gly Asp Ala Pro His Thr
        115                 120                 125
Gly Gly Lys Pro Gly Gly Phe Asp Val Lys Ala Leu Arg Ala Phe Arg
    130                 135                 140
Val Leu Arg Pro Leu Arg Leu Val Ser Gly Val Pro Ser Leu His Ile
145                 150                 155                 160
Val Leu Asn Ser Ile Met Lys Ala Leu Val Pro Leu Leu His Ile Ala
                165                 170                 175
Leu Leu Val Leu Phe Val Ile Ile Ile Tyr Ala Ile Ile Gly Leu Glu
            180                 185                 190
Leu Phe Leu Gly Arg Met His Lys Thr Cys Tyr Phe Leu Gly Ser Asp
        195                 200                 205
Met Glu Ala Glu Glu Asp Pro Ser Pro Cys Ala Ser Ser Gly Ser Gly
    210                 215                 220
Arg Ala Cys Thr Leu Asn Gln Thr Glu Cys Arg Gly Arg Trp Pro Gly
225                 230                 235                 240
Pro Asn Gly Gly Ile Thr Asn Phe Asp Asn Phe Phe Phe Ala Met Leu
                245                 250                 255
Thr Val Phe Gln Cys Val Thr Met Glu Gly Trp Thr Asp Val Leu Tyr
            260                 265                 270
Trp Met Gln Asp Ala Met Gly Tyr Glu Leu Pro Trp Val Tyr Phe Val
        275                 280                 285
Ser Leu Val Ile Phe Gly Ser Phe Phe Val Leu Asn Leu Val Leu Gly
    290                 295                 300
Val Leu Ser Gly Glu Phe Ser Lys Glu Arg Glu Lys Ala Lys Ala Arg
305                 310                 315                 320
Gly Asp Phe Gln Lys Gln Arg Glu Lys Gln Gln Met Glu Glu Asp Leu
                325                 330                 335
Arg Gly Tyr Leu Asp Trp Ile Thr Gln Ala Glu Glu Leu Asp Met Glu
            340                 345                 350
Asp Pro Ser Ala Asp Asp Asn Leu Gly Ser Met Ala Glu Glu Gly Arg
        355                 360                 365
Ala Gly His Arg Pro Gln Leu Ala Glu Leu Thr Asn Arg Arg Arg Gly
    370                 375                 380
Arg Leu Arg Trp Phe Ser His Ser Thr Arg Ser Thr His Ser Thr Ser
385                 390                 395                 400
Ser His Ala Ser Leu Pro Ala Ser Asp Thr Gly Ser Met Thr Glu Thr
                405                 410                 415
Gln Gly Asp Glu Asp Glu Glu Glu Gly Ala Leu Ala Ser Cys Thr Arg
            420                 425                 430
Cys Leu Asn Lys Ile Met Lys Thr Arg Val Cys Arg Arg Leu Arg Arg
        435                 440                 445
Ala Asn Arg Val Leu Arg Ala Arg Cys Arg Arg Ala Val Lys Ser Asn
    450                 455                 460
Ala Cys Tyr Trp Ala Val Leu Leu Leu Val Phe Leu Asn Thr Leu Thr
465                 470                 475                 480
Ile Ala Ser Glu His His Gly Gln Pro Val Trp Leu Thr Gln Ile Gln
                485                 490                 495
Glu Tyr Ala Asn Lys Val Leu Leu Cys Leu Phe Thr Val Glu Met Leu
            500                 505                 510
Leu Lys Leu Tyr Gly Leu Gly Pro Ser Ala Tyr Val Ser Ser Phe Phe
        515                 520                 525
Asn Arg Phe Asp Cys Phe Val Val Cys Gly Gly Ile Leu Glu Thr Thr
    530                 535                 540
Leu Val Glu Val Gly Ala Met Gln Pro Leu Gly Ile Ser Val Leu Arg
545                 550                 555                 560
Cys Val Arg Leu Leu Arg Ile Phe Lys Val Thr Arg His Trp Ala Ser
                565                 570                 575
Leu Ser Asn Leu Val Ala Ser Leu Leu Asn Ser Met Lys Ser Ile Ala
            580                 585                 590
Ser Leu Leu Leu Leu Leu Phe Leu Phe Ile Ile Ile Phe Ser Leu Leu
        595                 600                 605
Gly Met Gln Leu Phe Gly Gly Lys Phe Asn Phe Asp Gln Thr His Thr
    610                 615                 620
Lys Arg Ser Thr Phe Asp Thr Phe Pro Gln Ala Leu Leu Thr Val Phe
625                 630                 635                 640
Gln Ile Leu Thr Gly Glu Asp Trp Asn Val Val Met Tyr Asp Gly Ile
                645                 650                 655
Met Ala Tyr Gly Gly Pro Phe Phe Pro Gly Met Leu Val Cys Ile Tyr
            660                 665                 670
Phe Ile Ile Leu Phe Ile Cys Gly Asn Tyr Ile Leu Leu Asn Val Phe
        675                 680                 685
Leu Ala Ile Ala Val Asp Asn Leu Ala Ser Gly Asp Ala Gly Thr Ala
    690                 695                 700
Lys Asp Lys Gly Gly Glu Lys Ser Asn Glu Lys Asp Leu Pro Gln Glu
705                 710                 715                 720
Asn Glu Gly Leu Val Pro Gly Val Glu Lys Glu Glu Glu Glu Gly Ala
                725                 730                 735
Arg Arg Glu Gly Ala Asp Met Glu Glu Glu Glu Glu Glu Glu Glu Glu
            740                 745                 750
Glu Glu Glu Glu Glu Glu Glu Glu Gly Ala Gly Gly Val Glu Leu Leu
        755                 760                 765
Gln Glu Val Val Pro Lys Glu Lys Val Val Pro Ile Pro Glu Gly Ser
    770                 775                 780
Ala Phe Phe Cys Leu Ser Gln Thr Asn Pro Leu Arg Lys Gly Cys His
785                 790                 795                 800
Thr Leu Ile His His His Val Phe Thr Asn Leu Ile Leu Val Phe Ile
                805                 810                 815
Ile Leu Ser Ser Val Ser Leu Ala Ala Glu Asp Pro Ile Arg Ala His
            820                 825                 830
Ser Phe Arg Asn His Ile Leu Gly Tyr Phe Asp Tyr Ala Phe Thr Ser
        835                 840                 845
Ile Phe Thr Val Glu Ile Leu Leu Lys Met Thr Val Phe Gly Ala Phe
    850                 855                 860
Leu His Arg Gly Ser Phe Cys Arg Ser Trp Phe Asn Met Leu Asp Leu
865                 870                 875                 880
Leu Val Val Ser Val Ser Leu Ile Ser Phe Gly Ile His Ser Ser Ala
                885                 890                 895
Ile Ser Val Val Lys Ile Leu Arg Val Leu Arg Val Leu Arg Pro Leu
            900                 905                 910
Arg Ala Ile Asn Arg Ala Lys Gly Leu Lys His Val Val Gln Cys Val
        915                 920                 925
Phe Val Ala Ile Arg Thr Ile Gly Asn Ile Met Ile Val Thr Thr Leu
    930                 935                 940
Leu Gln Phe Met Phe Ala Cys Ile Gly Val Gln Leu Phe Lys Gly Lys
945                 950                 955                 960
Phe Tyr Thr Cys Thr Asp Glu Ala Lys His Thr Pro Gln Glu Cys Lys
                965                 970                 975
Gly Ser Phe Leu Val Tyr Pro Asp Gly Asp Val Ser Arg Pro Leu Val
            980                 985                 990
Arg Glu Arg Leu Trp Val Asn Ser Asp Phe Asn Phe Asp Asn Val Leu
        995                 1000                1005
Ser Ala Met Met Ala Leu Phe Thr Val Ser Thr Phe Glu Gly Trp
    1010                1015                1020
Pro Ala Leu Leu Tyr Lys Ala Ile Asp Ala Tyr Ala Glu Asp His
    1025                1030                1035
Gly Pro Ile Tyr Asn Tyr Arg Val Glu Ile Ser Val Phe Phe Ile
    1040                1045                1050
Val Tyr Ile Ile Ile Ile Ala Phe Phe Met Met Asn Ile Phe Val
    1055                1060                1065
Gly Phe Val Ile Ile Thr Phe Arg Ala Gln Gly Glu Gln Glu Tyr
    1070                1075                1080
Gln Asn Cys Glu Leu Asp Lys Asn Gln Arg Gln Cys Val Glu Tyr
    1085                1090                1095
Ala Leu Lys Ala Gln Pro Leu Arg Arg Tyr Ile Pro Lys Asn Pro
    1100                1105                1110
His Gln Tyr Arg Val Trp Ala Thr Val Asn Ser Ala Ala Phe Glu
    1115                1120                1125
Tyr Leu Met Phe Leu Leu Ile Leu Leu Asn Thr Val Ala Leu Ala
    1130                1135                1140
Met Gln His Tyr Glu Gln Thr Ala Pro Phe Asn Tyr Ala Met Asp
    1145                1150                1155
Ile Leu Asn Met Val Phe Thr Gly Leu Phe Thr Ile Glu Met Val
    1160                1165                1170
Leu Lys Ile Ile Ala Phe Lys Pro Lys His Tyr Phe Thr Asp Ala
    1175                1180                1185
Trp Asn Thr Phe Asp Ala Leu Ile Val Val Gly Ser Ile Val Asp
    1190                1195                1200
Ile Ala Val Thr Glu Val Asn Asn Gly Gly His Leu Gly Glu Ser
    1205                1210                1215
Ser Glu Asp Ser Ser Arg Ile Ser Ile Thr Phe Phe Arg Leu Phe
    1220                1225                1230
Arg Val Met Arg Leu Val Lys Leu Leu Ser Lys Gly Glu Gly Ile
    1235                1240                1245
Arg Thr Leu Leu Trp Thr Phe Ile Lys Ser Phe Gln Ala Leu Pro
    1250                1255                1260
Tyr Val Ala Leu Leu Ile Ala Met Ile Phe Phe Ile Tyr Ala Val
    1265                1270                1275
Ile Gly Met Gln Met Phe Gly Lys Val Ala Leu Gln Asp Gly Thr
    1280                1285                1290
Gln Ile Asn Arg Asn Asn Asn Phe Gln Thr Phe Pro Gln Ala Val
    1295                1300                1305
Leu Leu Leu Phe Arg Cys Ala Thr Gly Glu Ala Trp Gln Glu Ile
    1310                1315                1320
Met Leu Ala Ser Leu Pro Gly Asn Arg Cys Asp Pro Glu Ser Asp
    1325                1330                1335
Phe Gly Pro Gly Glu Glu Phe Thr Cys Gly Ser Asn Phe Ala Ile
    1340                1345                1350
Ala Tyr Phe Ile Ser Phe Phe Met Leu Cys Ala Phe Leu Ile Ile
    1355                1360                1365
Asn Leu Phe Val Ala Val Ile Met Asp Asn Phe Asp Tyr Leu Thr
    1370                1375                1380
Arg Asp Trp Ser Ile Leu Gly Pro His His Leu Asp Glu Phe Lys
    1385                1390                1395
Arg Ile Trp Ser Glu Tyr Asp Pro Gly Ala Lys Gly Arg Ile Lys
    1400                1405                1410
His Leu Asp Val Val Ala Leu Leu Arg Arg Ile Gln Pro Pro Leu
    1415                1420                1425
Gly Phe Gly Lys Leu Cys Pro His Arg Val Ala Cys Lys Arg Leu
    1430                1435                1440
Val Ala Met Asn Met Pro Leu Asn Ser Asp Gly Thr Val Thr Phe
    1445                1450                1455
Asn Ala Thr Leu Phe Ala Leu Val Arg Thr Ser Leu Lys Ile Lys
    1460                1465                1470
Thr Glu Gly Asn Leu Glu Gln Ala Asn Gln Glu Leu Arg Ile Val
    1475                1480                1485
Ile Lys Lys Ile Trp Lys Arg Met Lys Gln Lys Leu Leu Asp Glu
    1490                1495                1500
Val Ile Pro Pro Pro Asp Glu Glu Glu Val Thr Val Gly Lys Phe
    1505                1510                1515
Tyr Ala Thr Phe Leu Ile Gln Asp Tyr Phe Arg Lys Phe Arg Arg
    1520                1525                1530
Arg Lys Glu Lys Gly Leu Leu Gly Asn Asp Ala Ala Pro Ser Thr
    1535                1540                1545
Ser Ser Ala Leu Gln Ala Gly Leu Arg Ser Leu Gln Asp Leu Gly
    1550                1555                1560
Pro Glu Met Arg Gln Ala Leu Thr Cys Asp Thr Glu Glu Glu Glu
    1565                1570                1575
Glu Glu Gly Gln Glu Gly Val Glu Glu Glu Asp Glu Lys Asp Leu
    1580                1585                1590
Glu Thr Asn Lys Ala Thr Met Val Ser Gln Pro Ser Ala Arg Arg
    1595                1600                1605
Gly Ser Gly Ile Ser Val Ser Leu Pro Val Gly Asp Arg Leu Pro
    1610                1615                1620
Asp Ser Leu Ser Phe Gly Pro Ser Asp Asp Asp Arg Gly Thr Pro
    1625                1630                1635
Thr Ser Ser Gln Pro Ser Val Pro Gln Ala Gly Ser Asn Thr His
    1640                1645                1650
Arg Arg Gly Ser Gly Ala Leu Ile Phe Thr Ile Pro Glu Glu Gly
    1655                1660                1665
Asn Ser Gln Pro Lys Gly Thr Lys Gly Gln Asn Lys Gln Asp Glu
    1670                1675                1680
Asp Glu Glu Val Pro Asp Arg Leu Ser Tyr Leu Asp Glu Gln Ala
    1685                1690                1695
Gly Thr Pro Pro Cys Ser Val Leu Leu Pro Pro His Arg Ala Gln
    1700                1705                1710
Arg Tyr Met Asp Gly His Leu Val Pro Arg Arg Arg Leu Leu Pro
    1715                1720                1725
Pro Thr Pro Ala Gly Arg Lys Pro Ser Phe Thr Ile Gln Cys Leu
    1730                1735                1740
Gln Arg Gln Gly Ser Cys Glu Asp Leu Pro Ile Pro Gly Thr Tyr
    1745                1750                1755
His Arg Gly Arg Asn Ser Gly Pro Asn Arg Ala Gln Gly Ser Trp
    1760                1765                1770
Ala Thr Pro Pro Gln Arg Gly Arg Leu Leu Tyr Ala Pro Leu Leu
    1775                1780                1785
Leu Val Glu Glu Gly Ala Ala Gly Glu Gly Tyr Leu Gly Arg Ser
    1790                1795                1800
Ser Gly Pro Leu Arg Thr Phe Thr Cys Leu His Val Pro Gly Thr
    1805                1810                1815
His Ser Asp Pro Ser His Gly Lys Arg Gly Ser Ala Asp Ser Leu
    1820                1825                1830
Val Glu Ala Val Leu Ile Ser Glu Gly Leu Gly Leu Phe Ala Arg
    1835                1840                1845
Asp Pro Arg Phe Val Ala Leu Ala Lys Gln Glu Ile Ala Asp Ala
    1850                1855                1860
Cys Arg Leu Thr Leu Asp Glu Met Asp Asn Ala Ala Ser Asp Leu
    1865                1870                1875
Leu Ala Gln Gly Thr Ser Ser Leu Tyr Ser Asp Glu Glu Ser Ile
    1880                1885                1890
Leu Ser Arg Phe Asp Glu Glu Asp Leu Gly Asp Glu Met Ala Cys
    1895                1900                1905
Val His  Ala Leu
    1910
 
           
             3 
             6112 
             DNA 
             homo sapiens 
           
            3
ctccaaagct gggggaagag aggggggttg tgtgcagatg gcccttcaat ctcgaaagaa     60
agatgtcgga atctgaaggc gggaaagaca ccaccccaga gcccagtcca gccaatgggg    120
caggccctgg tcccgaatgg gggctgtgcc ccgggccccc agctgtggaa ggtgaaagca    180
gtggggcatc aggcctaggg acccctaagc gaagaaacca gcacagcaag cacaagacag    240
tggcagtggc cagtgcccag cggtcacctc gggcactctt ctgcctcacc ctggccaatc    300
ctctgcgacg gtcctgcatc agcatcgtgg agtggaagcc cttcgacatc ctcatcctgc    360
tgaccatctt tgccaactgc gtggccctgg gagtttacat ccccttccct gaggacgact    420
ccaacactgc caaccacaac ctggagcagg tggagtacgt attcctggtg attttcactg    480
tggagacggt gctcaagatc gtggcctacg ggctggtgct ccaccccagc gcctacatcc    540
gcaatggctg gaacctactc gacttcatca tcgtcgtggt cgggctgttc agcgttctgc    600
tggagcaggg ccccggacgg ccaggcgacg ccccgcacac cgggggaaag ccaggaggct    660
tcgatgtgaa ggcattgagg gcgtttcggg tgctgcggcc actgaggctg gtgtctgggg    720
tcccgagcct gcacatagtg ctcaattcca tcatgaaggc tctggtgccg ctgctgcaca    780
ttgcactgct cgtgctcttc gtcatcatca tttatgccat cattgggctc gagctgttcc    840
ttggacgaat gcacaagacg tgctacttcc tgggatccga catggaagcg gaggaggacc    900
catcgccctg tgcgtcttcg ggatcagggc gtgcgtgcac gctgaaccag actgagtgcc    960
gcgggcgctg gccagggccc aatggaggca tcaccaactt tgacaacttc ttcttcgcca   1020
tgctgacagt cttccagtgt gtcaccatgg aaggctggac cgatgtgctc tactggatgc   1080
aagatgccat ggggtatgaa ctgccctggg tgtactttgt gagccttgtc atctttgggt   1140
ccttcttcgt cctcaacctt gtgcttggcg tcctgagtgg ggagttctcc aaggagagag   1200
agaaagcgaa agctcgcggg gacttccaga agcagcggga gaagcagcag atggaggaag   1260
acctgcgggg ctacctggac tggatcactc aagccgaaga gctggacatg gaggacccct   1320
ccgccgatga caaccttggt tctatggctg aagagggccg ggcgggccat cggccacagc   1380
tggccgagct gaccaatagg aggcgtggac gtctgcgctg gttcagtcat tctactcgct   1440
ccacacactc caccagcagc catgccagcc tcccagccag tgacaccggt tccatgacag   1500
agacccaagg cgatgaggat gaggaggagg gggctctggc cagctgtaca cgctgcctaa   1560
acaagatcat gaaaaccaga gtctgccgcc gcctccgccg agccaaccgg gtccttcggg   1620
cacgctgccg tcgggcagtg aagtccaatg cctgctactg ggctgtgctg ttgctcgtct   1680
tcctcaacac gttgaccatc gcctctgagc accacgggca gcctgtgtgg ctcacccaga   1740
tccaggagta tgccaacaaa gtgttgctct gtctgttcac ggtggagatg cttctcaaat   1800
tgtacggtct gggcccctct gcctatgtgt cttccttctt caaccgcttt gactgctttg   1860
tggtctgtgg gggcatccta gagaccacct tggtggaggt gggcgccatg cagcccttgg   1920
gcatctcagt gctccgatgt gtgcgcctcc tcaggatctt taaggtcacc agacactggg   1980
cttctctgag caatctggtg gcatccctgc tcaattcaat gaaatccatc gcatccttgc   2040
tgcttctcct cttcctcttc atcattatct tctccctgct tggcatgcag ctgtttgggg   2100
gcaagttcaa ctttgaccag acccacacca agcgaagcac ctttgacacg ttcccccagg   2160
ccctcctcac tgtctttcag atcctgacag gtgaggactg gaacgtggtc atgtatgatg   2220
gtatcatggc atatggtggc cccttcttcc caggaatgtt ggtgtgcatc tatttcatca   2280
ttctcttcat ctgtggcaac tacatcctgt tgaacgtgtt tcttgccatt gctgtggaca   2340
acctggccag tggagatgca ggcactgcca aggacaaggg cggggagaag agcaatgaga   2400
aggatctccc acaggagaat gaaggcctgg tgcctggtgt ggagaaagag gaagaggagg   2460
gtgcaaggag ggaaggagca gacatggagg aggaggagga ggaggaagaa gaggaagaag   2520
aggaagaaga ggaagagggt gcagggggtg tggaactcct gcaggaagtt gtacccaagg   2580
agaaggtggt acccatccct gagggcagcg ccttcttctg cctcagccaa accaacccgc   2640
tgaggaaggg ctgccacacc ctcatccacc atcatgtctt caccaatctt atcctggtgt   2700
tcatcatcct cagcagtgtg tccctggccg ctgaggaccc catccgagcc cactccttcc   2760
gcaaccatat tctgggttac ttcgattatg ccttcacctc cattttcact gtggagattc   2820
tactaaagat gacagtgttt ggggccttcc tgcaccgcgg ctccttctgc cgtagctggt   2880
ttaatatgtt ggatctgctg gtggtcagtg tgtccctcat ctcctttggc atccactcca   2940
gcgccatctc ggtggtgaag attctgcgag tactccgagt actgcggccc ctccgagcca   3000
tcaacagggc caagggactc aagcatgtgg tgcagtgtgt atttgtggcc atccggacca   3060
tcggaaacat catgattgtc accacacttc tgcaatttat gttcgcctgc atcggggtgc   3120
agctcttcaa ggggaaattc tacacctgca cggacgaggc caaacacacc cctcaagaat   3180
gcaagggctc cttcctggta tacccagatg gagacgtgtc acggcccctg gtccgggagc   3240
ggctctgggt caacagtgat ttcaactttg acaatgtcct ttcagccatg atggccctgt   3300
tcactgtctc cacctttgaa ggctggcctg cactgctata caaggccatc gatgcatatg   3360
cagaggacca tggccccatc tataattacc gtgtggagat ctcagtgttc ttcattgtct   3420
acztcatcat cattgcgttc ttcatgatga acatcttcgt gggcttcgtc atcatcactt   3480
tccgtgccca gggcgagcag gagtaccaaa actgtgagct ggacaagaac cagcgtcaat   3540
gtgtggaata tgccctcaag gcccagccac tccgccgtta catccccaag aacccgcatc   3600
atgtggaata gtgggccact gtgaactctg ctgcctttga gtacctgatg ttcctgctca   3660
tcctgctcaa cacagttgcc ctagccatgc agcactatga gcagactgct cccttcaact   3720
atgccatgga catcctcaac atggtcttca ctggcctctt cactattgag atggtgctca   3780
aaatcatcgc cttcaagccc aagcattact tcactgatgc ctggaacacg tttgacgctc   3840
ttattgtggt gggcagcata gtggatattg ccgtcactga agtcaataat ggtggccacc   3900
ttggcgagag ctctgaggac agctcccgca tttccattac cttctttcgc ctcttccgag   3960
ttatgcggct ggtcaagctt ctcagtaagg gtgaagggat ccgcacattg ctctggacat   4020
tcatcaagtc cttccaggcc ttgccctatg tggctcttct catcgcaatg atattcttca   4080
tctatgccgt cattggcatg cagatgttcg gcaaggtggc tcttcaggat ggcacacaga   4140
taaaccgaaa caacaacttc cagacctttc cacaggctgt gctgcttctg ttcaggtgtg   4200
ccaacggtga ggcatggcag gagataatgc ttgccagcct tcccggaaat cggtgtgatc   4260
ctgagtctga cttcggccct ggtgaagagt ttacctgtgg tagcaatttt gccatcgcct   4320
attcattcag cttcttcatg ctctgtgcct tcctgatcat aaatctcttt gtggctgtga   4380
tcatggacaa ctttgattat ctcaccagag attggtccat cctgggcccc catcaccttg   4440
atgaattcaa gaggatctgg tctgaatatg accctggggc caagggccgc atcaaacact   4500
tggatgtggt tgccctgctg agacgtatcc agccccctct gggatttggg aagctgtgcc   4560
cacaccgagt ggcctgcaag agacttgtgg caatgaacat gcccctcaac tcagatggga   4620
cggtgacatt caacgccaca ctctttgccc tggtccggac atccctgaag atcaaaacag   4680
aagggaacct ggagcaagcc aaccaggagc tgcggattgt catcaaaaag atctggaagc   4740
ggatgaaaca gaagctgcta gatgaggtca tccccccacc agacgaggag gaggtcaccg   4800
tgggcaaatt ctacgccaca tttctgatcc aggactattt ccgcaaattc cggcggagga   4860
aagaaaaagg gctactaggc aacgacgccg cccctagcac ctcttccgcc cttcaggctg   4920
gtctgcggag cctgcaggac ttgggtcctg agatgcggca ggccctcacc tgtgacacag   4980
aggaggagga agaagagggg caggagggag tggaggagga agatgaaaag gacttggaaa   5040
ctaacaaagc cacgatggtc tcccagccct cagctcgccg gggctccggg atttctgtgt   5100
ctctgcctgt cggggacaga cttccagatt cactctcctt tgggcccagt gatgatgaca   5160
gggggactcc cacctccagt cagcccagtg tgccccaggc tggatccaac acccacagga   5220
gaggctctgg ggctctcatt ttcaccatcc cagaagaagg aaattctcag cccaagggaa   5280
ccaaagggca aaacaagcaa gatgaggatg aggaagtccc tgatcggctt tcctacctag   5340
algagcaggc agggactccc ccgtgctcag tccttttgcc acctcacaga gctcagagat   5400
acatggatgg gcacctggta ccacgccgcc gtctgctgcc ccccacacct gcaggtcgga   5460
agcccctctt caccatccag tgtctgcagc gccagggcag ttgtgaggat ttacccatcc   5520
caggcaccta tcatcgtggg cgaaattcag ggcccaatag ggctcagggt tcctgggcaa   5580
caccacctca gcggggtcgg ctcctgtatg ccccgctgtt gttggtggaa gagggcgcag   5640
cgggggaggg gtacctcggc agatccagtg gcccactgcg caccttcacc tgtctgcacg   5700
tgcctggaac ccactcggac cccagccatg ggaagagggg cagtgccgac agcttggtgg   5760
aggctgtgct tatctcagag ggtctgggcc tctttgctcg agacccacgt ttcgtggccc   5820
tggccaagca ggagattgca gatgcgtgtc gcctgacgct ggatgagatg gacaatgctg   5880
ccagtgacct gctggcacag ggaaccagct ctctctatag cgacgaggag tccatcctct   5940
cccgcttcga tgaggaggac ttgggagacg agatggcctg cgtccacgcc ctctgaattc   6000
ccacccctcc ccaactgctc aataaacctc ctgccctccc ctccccagca ggaggcaggc   6060
atggaccaca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa           6112
 
           
             4 
             1977 
             PRT 
             Homo sapiens 
           
            4
Met Ser Glu Ser Glu Gly Gly Lys Asp Thr Thr Pro Glu Pro Ser Pro
1               5                   10                  15
Ala Asn Gly Ala Gly Pro Gly Pro Glu Trp Gly Leu Cys Pro Gly Pro
            20                  25                  30
Pro Ala Val Glu Gly Glu Ser Ser Gly Ala Ser Gly Leu Gly Thr Pro
        35                  40                  45
Lys Arg Arg Asn Gln His Ser Lys His Lys Thr Val Ala Val Ala Ser
    50                  55                  60
Ala Gln Arg Ser Pro Arg Ala Leu Phe Cys Leu Thr Leu Ala Asn Pro
65                  70                  75                  80
Leu Arg Arg Ser Cys Ile Ser Ile Val Glu Trp Lys Pro Phe Asp Ile
                85                  90                  95
Leu Ile Leu Leu Thr Ile Phe Ala Asn Cys Val Ala Leu Gly Val Tyr
            100                 105                 110
Ile Pro Phe Pro Glu Asp Asp Ser Asn Thr Ala Asn His Asn Leu Glu
        115                 120                 125
Gln Val Glu Tyr Val Phe Leu Val Ile Phe Thr Val Glu Thr Val Leu
    130                 135                 140
Lys Ile Val Ala Tyr Gly Leu Val Leu His Pro Ser Ala Tyr Ile Arg
145                 150                 155                 160
Asn Gly Trp Asn Leu Leu Asp Phe Ile Ile Val Val Val Gly Leu Phe
                165                 170                 175
Ser Val Leu Leu Glu Gln Gly Pro Gly Arg Pro Gly Asp Ala Pro His
            180                 185                 190
Thr Gly Gly Lys Pro Gly Gly Phe Asp Val Lys Ala Leu Arg Ala Phe
        195                 200                 205
Arg Val Leu Arg Pro Leu Arg Leu Val Ser Gly Val Pro Ser Leu His
    210                 215                 220
Ile Val Leu Asn Ser Ile Met Lys Ala Leu Val Pro Leu Leu His Ile
225                 230                 235                 240
Ala Leu Leu Val Leu Phe Val Ile Ile Ile Tyr Ala Ile Ile Gly Leu
                245                 250                 255
Glu Leu Phe Leu Gly Arg Met His Lys Thr Cys Tyr Phe Leu Gly Ser
            260                 265                 270
Asp Met Glu Ala Glu Glu Asp Pro Ser Pro Cys Ala Ser Ser Gly Ser
        275                 280                 285
Gly Arg Ala Cys Thr Leu Asn Gln Thr Glu Cys Arg Gly Arg Trp Pro
    290                 295                 300
Gly Pro Asn Gly Gly Ile Thr Asn Phe Asp Asn Phe Phe Phe Ala Met
305                 310                 315                 320
Leu Thr Val Phe Gln Cys Val Thr Met Glu Gly Trp Thr Asp Val Leu
                325                 330                 335
Tyr Trp Met Gln Asp Ala Met Gly Tyr Glu Leu Pro Trp Val Tyr Phe
            340                 345                 350
Val Ser Leu Val Ile Phe Gly Ser Phe Phe Val Leu Asn Leu Val Leu
        355                 360                 365
Gly Val Leu Ser Gly Glu Phe Ser Lys Glu Arg Glu Lys Ala Lys Ala
    370                 375                 380
Arg Gly Asp Phe Gln Lys Gln Arg Glu Lys Gln Gln Met Glu Glu Asp
385                 390                 395                 400
Leu Arg Gly Tyr Leu Asp Trp Ile Thr Gln Ala Glu Glu Leu Asp Met
                405                 410                 415
Glu Asp Pro Ser Ala Asp Asp Asn Leu Gly Ser Met Ala Glu Glu Gly
            420                 425                 430
Arg Ala Gly His Arg Pro Gln Leu Ala Glu Leu Thr Asn Arg Arg Arg
        435                 440                 445
Gly Arg Leu Arg Trp Phe Ser His Ser Thr Arg Ser Thr His Ser Thr
    450                 455                 460
Ser Ser His Ala Ser Leu Pro Ala Ser Asp Thr Gly Ser Met Thr Glu
465                 470                 475                 480
Thr Gln Gly Asp Glu Asp Glu Glu Glu Gly Ala Leu Ala Ser Cys Thr
                485                 490                 495
Arg Cys Leu Asn Lys Ile Met Lys Thr Arg Val Cys Arg Arg Leu Arg
            500                 505                 510
Arg Ala Asn Arg Val Leu Arg Ala Arg Cys Arg Arg Ala Val Lys Ser
        515                 520                 525
Asn Ala Cys Tyr Trp Ala Val Leu Leu Leu Val Phe Leu Asn Thr Leu
    530                 535                 540
Thr Ile Ala Ser Glu His His Gly Gln Pro Val Trp Leu Thr Gln Ile
545                 550                 555                 560
Gln Glu Tyr Ala Asn Lys Val Leu Leu Cys Leu Phe Thr Val Glu Met
                565                 570                 575
Leu Leu Lys Leu Tyr Gly Leu Gly Pro Ser Ala Tyr Val Ser Ser Phe
            580                 585                 590
Phe Asn Arg Phe Asp Cys Phe Val Val Cys Gly Gly Ile Leu Glu Thr
        595                 600                 605
Thr Leu Val Glu Val Gly Ala Met Gln Pro Leu Gly Ile Ser Val Leu
    610                 615                 620
Arg Cys Val Arg Leu Leu Arg Ile Phe Lys Val Thr Arg His Trp Ala
625                 630                 635                 640
Ser Leu Ser Asn Leu Val Ala Ser Leu Leu Asn Ser Met Lys Ser Ile
                645                 650                 655
Ala Ser Leu Leu Leu Leu Leu Phe Leu Phe Ile Ile Ile Phe Ser Leu
            660                 665                 670
Leu Gly Met Gln Leu Phe Gly Gly Lys Phe Asn Phe Asp Gln Thr His
        675                 680                 685
Thr Lys Arg Ser Thr Phe Asp Thr Phe Pro Gln Ala Leu Leu Thr Val
    690                 695                 700
Phe Gln Ile Leu Thr Gly Glu Asp Trp Asn Val Val Met Tyr Asp Gly
705                 710                 715                 720
Ile Met Ala Tyr Gly Gly Pro Phe Phe Pro Gly Met Leu Val Cys Ile
                725                 730                 735
Tyr Phe Ile Ile Leu Phe Ile Cys Gly Asn Tyr Ile Leu Leu Asn Val
            740                 745                 750
Phe Leu Ala Ile Ala Val Asp Asn Leu Ala Ser Gly Asp Ala Gly Thr
        755                 760                 765
Ala Lys Asp Lys Gly Gly Glu Lys Ser Asn Glu Lys Asp Leu Pro Gln
    770                 775                 780
Glu Asn Glu Gly Leu Val Pro Gly Val Glu Lys Glu Glu Glu Glu Gly
785                 790                 795                 800
Ala Arg Arg Glu Gly Ala Asp Met Glu Glu Glu Glu Glu Glu Glu Glu
                805                 810                 815
Glu Glu Glu Glu Glu Glu Glu Glu Glu Gly Ala Gly Gly Val Glu Leu
            820                 825                 830
Leu Gln Glu Val Val Pro Lys Glu Lys Val Val Pro Ile Pro Glu Gly
        835                 840                 845
Ser Ala Phe Phe Cys Leu Ser Gln Thr Asn Pro Leu Arg Lys Gly Cys
    850                 855                 860
His Thr Leu Ile His His His Val Phe Thr Asn Leu Ile Leu Val Phe
865                 870                 875                 880
Ile Ile Leu Ser Ser Val Ser Leu Ala Ala Glu Asp Pro Ile Arg Ala
                885                 890                 895
His Ser Phe Arg Asn His Ile Leu Gly Tyr Phe Asp Tyr Ala Phe Thr
            900                 905                 910
Ser Ile Phe Thr Val Glu Ile Leu Leu Lys Met Thr Val Phe Gly Ala
        915                 920                 925
Phe Leu His Arg Gly Ser Phe Cys Arg Ser Trp Phe Asn Met Leu Asp
    930                 935                 940
Leu Leu Val Val Ser Val Ser Leu Ile Ser Phe Gly Ile His Ser Ser
945                 950                 955                 960
Ala Ile Ser Val Val Lys Ile Leu Arg Val Leu Arg Val Leu Arg Pro
                965                 970                 975
Leu Arg Ala Ile Asn Arg Ala Lys Gly Leu Lys His Val Val Gln Cys
            980                 985                 990
Val Phe Val Ala Ile Arg Thr Ile  Gly Asn Ile Met Ile  Val Thr Thr
        995                 1000                 1005
Leu Leu  Gln Phe Met Phe Ala  Cys Ile Gly Val Gln  Leu Phe Lys
    1010                 1015                 1020
Gly Lys  Phe Tyr Thr Cys Thr  Asp Glu Ala Lys His  Thr Pro Gln
    1025                 1030                 1035
Glu Cys  Lys Gly Ser Phe Leu  Val Tyr Pro Asp Gly  Asp Val Ser
    1040                 1045                 1050
Arg Pro  Leu Val Arg Glu Arg  Leu Trp Val Asn Ser  Asp Phe Asn
    1055                 1060                 1065
Phe Asp  Asn Val Leu Ser Ala  Met Met Ala Leu Phe  Thr Val Ser
    1070                 1075                 1080
Thr Phe  Glu Gly Trp Pro Ala  Leu Leu Tyr Lys Ala  Ile Asp Ala
    1085                 1090                 1095
Tyr Ala  Glu Asp His Gly Pro  Ile Tyr Asn Tyr Arg  Val Glu Ile
    1100                 1105                 1110
Ser Val  Phe Phe Ile Val Tyr  Ile Ile Ile Ile Ala  Phe Phe Met
    1115                 1120                 1125
Met Asn  Ile Phe Val Gly Phe  Val Ile Ile Thr Phe  Arg Ala Gln
    1130                 1135                 1140
Gly Glu  Gln Glu Tyr Gln Asn  Cys Glu Leu Asp Lys  Asn Gln Arg
    1145                 1150                 1155
Gln Cys  Val Glu Tyr Ala Leu  Lys Ala Gln Pro Leu  Arg Arg Tyr
    1160                 1165                 1170
Ile Pro  Lys Asn Pro His Gln  Tyr Arg Val Trp Ala  Thr Val Asn
    1175                 1180                 1185
Ser Ala  Ala Phe Glu Tyr Leu  Met Phe Leu Leu Ile  Leu Leu Asn
    1190                 1195                 1200
Thr Val  Ala Leu Ala Met Gln  His Tyr Glu Gln Thr  Ala Pro Phe
    1205                 1210                 1215
Asn Tyr  Ala Met Asp Ile Leu  Asn Met Val Phe Thr  Gly Leu Phe
    1220                 1225                 1230
Thr Ile  Glu Met Val Leu Lys  Ile Ile Ala Phe Lys  Pro Lys His
    1235                 1240                 1245
Tyr Phe  Thr Asp Ala Trp Asn  Thr Phe Asp Ala Leu  Ile Val Val
    1250                 1255                 1260
Gly Ser  Ile Val Asp Ile Ala  Val Thr Glu Val Asn  Asn Gly Gly
    1265                 1270                 1275
His Leu  Gly Glu Ser Ser Glu  Asp Ser Ser Arg Ile  Ser Ile Thr
    1280                 1285                 1290
Phe Phe  Arg Leu Phe Arg Val  Met Arg Leu Val Lys  Leu Leu Ser
    1295                 1300                 1305
Lys Gly  Glu Gly Ile Arg Thr  Leu Leu Trp Thr Phe  Ile Lys Ser
    1310                 1315                 1320
Phe Gln  Ala Leu Pro Tyr Val  Ala Leu Leu Ile Ala  Met Ile Phe
    1325                 1330                 1335
Phe Ile  Tyr Ala Val Ile Gly  Met Gln Met Phe Gly  Lys Val Ala
    1340                 1345                 1350
Leu Gln  Asp Gly Thr Gln Ile  Asn Arg Asn Asn Asn  Phe Gln Thr
    1355                 1360                 1365
Phe Pro  Gln Ala Val Leu Leu  Leu Phe Arg Cys Ala  Thr Gly Glu
    1370                 1375                 1380
Ala Trp  Gln Glu Ile Met Leu  Ala Ser Leu Pro Gly  Asn Arg Cys
    1385                 1390                 1395
Asp Pro  Glu Ser Asp Phe Gly  Pro Gly Glu Glu Phe  Thr Cys Gly
    1400                 1405                 1410
Ser Asn  Phe Ala Ile Ala Tyr  Phe Ile Ser Phe Phe  Met Leu Cys
    1415                 1420                 1425
Ala Phe  Leu Ile Ile Asn Leu  Phe Val Ala Val Ile  Met Asp Asn
    1430                 1435                 1440
Phe Asp  Tyr Leu Thr Arg Asp  Trp Ser Ile Leu Gly  Pro His His
    1445                 1450                 1455
Leu Asp  Glu Phe Lys Arg Ile  Trp Ser Glu Tyr Asp  Pro Gly Ala
    1460                 1465                 1470
Lys Gly  Arg Ile Lys His Leu  Asp Val Val Ala Leu  Leu Arg Arg
    1475                 1480                 1485
Ile Gln  Pro Pro Leu Gly Phe  Gly Lys Leu Cys Pro  His Arg Val
    1490                 1495                 1500
Ala Cys  Lys Arg Leu Val Ala  Met Asn Met Pro Leu  Asn Ser Asp
    1505                 1510                 1515
Gly Thr  Val Thr Phe Asn Ala  Thr Leu Phe Ala Leu  Val Arg Thr
    1520                 1525                 1530
Ser Leu  Lys Ile Lys Thr Glu  Gly Asn Leu Glu Gln  Ala Asn Gln
    1535                 1540                 1545
Glu Leu  Arg Ile Val Ile Lys  Lys Ile Trp Lys Arg  Met Lys Gln
    1550                 1555                 1560
Lys Leu  Leu Asp Glu Val Ile  Pro Pro Pro Asp Glu  Glu Glu Val
    1565                 1570                 1575
Thr Val  Gly Lys Phe Tyr Ala  Thr Phe Leu Ile Gln  Asp Tyr Phe
    1580                 1585                 1590
Arg Lys  Phe Arg Arg Arg Lys  Glu Lys Gly Leu Leu  Gly Asn Asp
    1595                 1600                 1605
Ala Ala  Pro Ser Thr Ser Ser  Ala Leu Gln Ala Gly  Leu Arg Ser
    1610                 1615                 1620
Leu Gln  Asp Leu Gly Pro Glu  Met Arg Gln Ala Leu  Thr Cys Asp
    1625                 1630                 1635
Thr Glu  Glu Glu Glu Glu Glu  Gly Gln Glu Gly Val  Glu Glu Glu
    1640                 1645                 1650
Asp Glu  Lys Asp Leu Glu Thr  Asn Lys Ala Thr Met  Val Ser Gln
    1655                 1660                 1665
Pro Ser  Ala Arg Arg Gly Ser  Gly Ile Ser Val Ser  Leu Pro Val
    1670                 1675                 1680
Gly Asp  Arg Leu Pro Asp Ser  Leu Ser Phe Gly Pro  Ser Asp Asp
    1685                 1690                 1695
Asp Arg  Gly Thr Pro Thr Ser  Ser Gln Pro Ser Val  Pro Gln Ala
    1700                 1705                 1710
Gly Ser  Asn Thr His Arg Arg  Gly Ser Gly Ala Leu  Ile Phe Thr
    1715                 1720                 1725
Ile Pro  Glu Glu Gly Asn Ser  Gln Pro Lys Gly Thr  Lys Gly Gln
    1730                 1735                 1740
Asn Lys  Gln Asp Glu Asp Glu  Glu Val Pro Asp Arg  Leu Ser Tyr
    1745                 1750                 1755
Leu Asp  Glu Gln Ala Gly Thr  Pro Pro Cys Ser Val  Leu Leu Pro
    1760                 1765                 1770
Pro His  Arg Ala Gln Arg Tyr  Met Asp Gly His Leu  Val Pro Arg
    1775                 1780                 1785
Arg Arg  Leu Leu Pro Pro Thr  Pro Ala Gly Arg Lys  Pro Ser Phe
    1790                 1795                 1800
Thr Ile  Gln Cys Leu Gln Arg  Gln Gly Ser Cys Glu  Asp Leu Pro
    1805                 1810                 1815
Ile Pro  Gly Thr Tyr His Arg  Gly Arg Asn Ser Gly  Pro Asn Arg
    1820                 1825                 1830
Ala Gln  Gly Ser Trp Ala Thr  Pro Pro Gln Arg Gly  Arg Leu Leu
    1835                 1840                 1845
Tyr Ala  Pro Leu Leu Leu Val  Glu Glu Gly Ala Ala  Gly Glu Gly
    1850                 1855                 1860
Tyr Leu  Gly Arg Ser Ser Gly  Pro Leu Arg Thr Phe  Thr Cys Leu
    1865                 1870                 1875
His Val  Pro Gly Thr His Ser  Asp Pro Ser His Gly  Lys Arg Gly
    1880                 1885                 1890
Ser Ala  Asp Ser Leu Val Glu  Ala Val Leu Ile Ser  Glu Gly Leu
    1895                 1900                 1905
Gly Leu  Phe Ala Arg Asp Pro  Arg Phe Val Ala Leu  Ala Lys Gln
    1910                 1915                 1920
Glu Ile  Ala Asp Ala Cys Arg  Leu Thr Leu Asp Glu  Met Asp Asn
    1925                 1930                 1935
Ala Ala  Ser Asp Leu Leu Ala  Gln Gly Thr Ser Ser  Leu Tyr Ser
    1940                 1945                 1950
Asp Glu  Glu Ser Ile Leu Ser  Arg Phe Asp Glu Glu  Asp Leu Gly
    1955                 1960                 1965
Asp Glu  Met Ala Cys Val His  Ala Leu
    1970                 1975
 
           
             5 
             6114 
             DNA 
             Mus musculus 
           
            5
aagatgggag gactgtgtgc atgatggtcc ttatatctcc tgaggaggat gtcggaatct     60
gaagtcggga aagatacaac cccagagccc agtccagcca atgggactgg ccctggccct    120
gaatgggggc tctgtcctgg gcctccaact gtggggactg ataccagcgg ggcgtcaggc    180
ctggggaccc caagaagaag gacccagcac aacaaacaca agactgtggc ggtggccagt    240
gctcagagat cacctcgagc gctcttctgc ctcaccctta ctaatcccat tcgtcggtcc    300
tgcatcagca ttgtagagtg gaagcctttt gatattctca tcctcctgac aatctttgcc    360
aactgcgtgg cattgggggt atatatcccc ttccctgagg acgactccaa cactgctaac    420
cacaacttgg aacaggtaga atacgtgttc ctggtgattt tcaccgtgga gacagtgctc    480
aagatcgtag cctatgggct ggtgctccat cccagcgcct atattcgcaa tggctggaac    540
ctgctcgact tcatcatcgt cgtggtcggg ctgttcagcg tgctgctgga acaaggacct    600
gggcggccag gagatgcccc gcatactgga ggaaagccag gaggcttcga tgtaaaggca    660
ctgcgggcat ttagggtgct acgacctcta aggctagtgt ctggggtccc gagtctgcac    720
atagtcgtca attccatcat gaaggcgctt gtgccgctgc tgcacattgc cctgttggtg    780
ctcttcgtca ttatcattta cgccatcatc ggactcgagc tattcctcgg acgaatgcac    840
aagacatgct acttcctggg atctgatatg gaagcagagg aggacccatc accttgtgca    900
tcttctggct ctgggcgttc atgcacactg aaccataccg agtgccgcgg gcgctggcca    960
ggacccaacg gtggcatcac gaacttcgac aattttttct ttgccatgct aactgtgttc   1020
cagtgtatta ccatggaagg ctggacagac gtcctctact ggatgcagga tgccatgggg   1080
tatgagctgc cttgggtgta ctttgtgagc cttgtcatct ttgggtcctt ctttgtcctc   1140
aaccttgtgc ttggagtcct aagcggggag ttctccaagg aaagagaaaa ggcaaaagca   1200
cgaggtgact ttcagaagct tcgggagaag cagcagatgg aagaagacct tcggggctac   1260
ctggactgga tcacacaggc tgaggagtta gaccttcatg acccctcagt agacggcaac   1320
ttggcttctc ttgctgaaga gggacgggcg ggccatcggc cacaactgtc agagctgacc   1380
aataggaggc gcggacggct gcgatggttc agccactcta ctcgctccac acactccacc   1440
agcagccacg ccagcctccc agccagtgac actggctcca tgacagacac ccctggagat   1500
gaggatgaag aagaggggac catggctagc tgtacacgct gcctaaacaa gattatgaaa   1560
acaaggatct gccgccactt ccgccgagcc aaccggggtc tccgtgcacg ctgccgccgg   1620
gccgtcaagt ccaacgcctg ctactgggct gtactgttgc tcgtcttcct caacacgttg   1680
accatcgctt cagagcacca tgggcagcct ttgtggctca cccagaccca agagtatgcc   1740
aacaaagttc tgctctgcct cttcactgtg gagatgctcc tcaaactgta cggcctgggc   1800
ccctctgtct acgttgcctc ctttttcaac cgctttgact gcttcgtggt ctgtgggggc   1860
atcctagaaa ccactttggt ggaggtgggg gccatgcagc ctcttggcat ctcagtgctc   1920
cgatgtgtac gtctcctcag gatcttcaag gtcaccaggc actgggcatc cctgagcaat   1980
ctggtggcat ctttgctcaa ttccatgaag tccatcgcct ccttgctgct tctcctcttt   2040
ctcttcatca tcatcttctc cctgcttggc atgcagctgt ttgggggcaa gttcaacttt   2100
gaccagaccc acaccaagag gagcaccttt gataccttcc cccaagccct cctcactgtc   2160
tttcagatcc tgactggtga ggattggaac gttgtcatgt atgatggtat catggcctac   2220
ggtgggccct tcttcccagg gatgctggtg tgtgtttatt tcatcatcct cttcatctgt   2280
ggcaactaca tcctgctgaa cgtgtttctt gccattgccg tggataacct agccagcggg   2340
gatgcaggca ctgccaaaga taagggcaga gagaagagca gtgaaggaaa ccctccaaag   2400
gagaacaaag tattggtgcc tggtggagag aatgaggacg caaagggcgc aagaagtgaa   2460
ggagcagcac caggcatgga ggaggaggag gaggaggagg aggaagaaga agaggaggag   2520
gaggaggaag aggaaaatgg tgcaggacat gtggaactct tgcaggaagt agtacccaag   2580
gagaaggtgg tacccatccc tgaaggcagt gccttcttct gccttagcca aaccaacccg   2640
cttcggaagg cctgccacac actcatacat caccatatct tcaccagtct catcctagtg   2700
ttcatcatcc tcagtagtgt gtccctggct gctgaggacc ccatccgagc tcactccttc   2760
cgaaaccata ttctgggata ttttgattat gccttcacct ccatattcac tgtggagatt   2820
ctactcaaga tgacagtgtt tggggccttc ctgcaccgag gctctttctg ccgtagctgg   2880
ttcaatctgt tggatctcct tgtggtcagt gtgtccctca tctccttcgg catccactcc   2940
agtgccatct cagttgtgaa gattctccga gtcctccgag tcctgcggcc tctccgagcc   3000
atcaacagag ccaagggact caagcatgtg gtgcagtgtg tgttcgtggc catccggacc   3060
atcggaaaca tcatgattgt caccaccctc ttgcagttca tgttcgcctg cattggtgtt   3120
cagctgttca agggaaaatt ctacagttgc actgatgagg ccaaacacac cctgaaagaa   3180
tcgaagggct ccttcctcat ctaccctgat ggagatgtgt cacgaccttt ggtccgggag   3240
cggctctggg tcaacagtga ttttaacttt gacaacgtcc tttcagccat gatggccctg   3300
ttcactgtct ctacctttga aggctggcct gcgctactat acaaggccat agatgcaaac   3360
gcagaagatg agggccctat ctacaattac catgtggaga tatcagtatt cttcattgtc   3420
tacatcatca tcatcgcctt cttcatgatg aacatctttg tgggctttgt tatcatcaca   3480
ttccgtgccc agggagagca ggagtaccaa aactgtgaac tggacaagaa ccagcgccag   3540
tgtgtggaat atgccctcaa agctcagcca ctccgccgat acatccctaa gaatcctcat   3600
cagtaccgcg tgtgggccac tgtgaactct cgtgcctttg agtacctcat gtttctgctc   3660
atcctgctca acacggtggc cctagccatg cagcactatg aacagactgc tccctttaac   3720
tatgccatgg acatcctcaa catggtcttc actggcctct tcaccattga gatggtgctc   3780
aaaatcatcg cctttaaacc caagcattac tttgcagatg cctggaatac gtttgatgct   3840
ctcattgtag tgggcagtgt agtcgacatc gccgtcacag aagtcaataa cggaggccat   3900
cttggcgaga gttcagagga cacgtcccgc atatctatca cgttctttcg cctcttccga   3960
gtcatgaggc tggtcaagct tctgagtaag ggtgaaggga tccgcacact gctctggaca   4020
ttcatcaagt ctttccaggc cttgccctat gtggcacttc tcatagcaat gatattcttc   4080
atctatgcag tcattggcat gcagatgttt ggcttggtgg ctcttcagga cggcacgcag   4140
ataaatcgaa acaacaattt ccagaccttt ccgcaggctg tgctgcttct gttcaggtgt   4200
gccactggtg aggcctggca agagataatg ctagccagcc ttccaggaaa tcgatgtgac   4260
cctgagtctg actttggccc aggcgaggaa tttacctgtg gtagcagttt tgccatcgtc   4320
tacttcatca gcttctttat gctctgtgcc ttcctgatta taaatctctt tgtggctgta   4380
atcatggata actttgatta cctaaccaga gattggtcta tcctgggacc ccaccacctt   4440
gatgaattca agaggatctg gtctgaatat gaccccggag ccaagggccg catcaagcac   4500
ttggatgtgg ttgccctgct gagacgcatc cagcccccat tgggatttgg aaagctatgc   4560
ccacaccgag tggcctgcaa gagactcgtg gcaatgaatg tgcccctcaa ctcagatgga   4620
acagtgacat tcaacgctac actctttgcc ctggtgcgga catccctgaa gatcaagaca   4680
gaagggaacc tggatcaagc caaccaggag cttcggatgg tcatcaaaaa gatctggaag   4740
cggataaagc agaaattgtt ggatgaggtc atccctcctc ccgatgagga ggaggtcact   4800
gtgggaaaat tctatgccac attcctgatc caagattatt tccgaaaatt ccggagaagg   4860
aaagaaaagg ggctactagg aagagaggcc ccaacaagca catcctctgc cctccaggct   4920
ggtctaagga gcctgcagga cttgggtcct gagatccgtc aagccctcac ctatgtcact   4980
gaggaagaag aggaagagga agaggcagtg ggtcaggagg ctgaggaaga ggaagctgag   5040
aacaacccag aaccatacaa agactccata gactcccagc cccaatctcg atggaactct   5100
aggatttcgg tgtctctacc tgttaaggag aaacttccag attctctctc aactgggccg   5160
agtgatgatg atgggctggc tcccaactcc aggcagccca gtgtgataca ggctggctcc   5220
caaccacaca ggagaagctc tggggttttc atgttcacta tcccggaaga aggaagtatt   5280
cagctcaagg gaactcaagg gcaggacaat cagaatgagg aacaggaact ccctgactgg   5340
actcctgacc tggatcgagc aggccgggac tccttcgaac ccagtccttt taccacctca   5400
ctggtccagc aacacgtaaa cgggcacatg tcgacgccga cgtttgctgc cccccacgcc   5460
tgcaggtcgg agccctcctt caccatccag tgtctgcaac gcctgggcag ttgtgaagat   5520
ttacctatcc caggcaccta ccatcgtgga cggacctcag gaccaagcag ggctcagggt   5580
tcctgggcag cccctcctca gaagggtcga ctgctatatg cccccctgtt gttggtggag   5640
gaatctacag tgggtgaagg ataccttggc aaacttggcg gcccactgcg taccttcacc   5700
tgtctgcaag tgcctggagc tcatccgaat cccagccacc gcaagagggg cagtgctgac   5760
agtttggtgg aggctgtgct catctccgaa ggcctaggtc tctttgccca agacccacga   5820
tttgtggccc tggccaagca ggagattgca gatgcatgtc acctgaccct ggatgagatg   5880
gacagtgctg ccagtgacct gctggcacag agaaccatct ccctttacag tgatgaggag   5940
tctattcttt cccgctttga tgaagaggac ctgggagatg agatggcctg tgtccatgcc   6000
ctctaaatcc ttacccctca tctactgctc aataaactcc ctgcccttcc ttcccccaga   6060
ggaggcaggc atggaccaca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa         6114
 
           
             6 
             1985 
             PRT 
             Mus musculus 
           
            6
Met Ser Glu Ser Glu Val Gly Lys Asp Thr Thr Pro Glu Pro Ser Pro
1               5                   10                  15
Ala Asn Gly Thr Gly Pro Gly Pro Glu Trp Gly Leu Cys Pro Gly Pro
            20                  25                  30
Pro Thr Val Gly Thr Asp Thr Ser Gly Ala Ser Gly Leu Gly Thr Pro
        35                  40                  45
Arg Arg Arg Thr Gln His Asn Lys His Lys Thr Val Ala Val Ala Ser
    50                  55                  60
Ala Gln Arg Ser Pro Arg Ala Leu Phe Cys Leu Thr Leu Thr Asn Pro
65                  70                  75                  80
Ile Arg Arg Ser Cys Ile Ser Ile Val Glu Trp Lys Pro Phe Asp Ile
                85                  90                  95
Leu Ile Leu Leu Thr Ile Phe Ala Asn Cys Val Ala Leu Gly Val Tyr
            100                 105                 110
Ile Pro Phe Pro Glu Asp Asp Ser Asn Thr Ala Asn His Asn Leu Glu
        115                 120                 125
Gln Val Glu Tyr Val Phe Leu Val Ile Phe Thr Val Glu Thr Val Leu
    130                 135                 140
Lys Ile Val Ala Tyr Gly Leu Val Leu His Pro Ser Ala Tyr Ile Arg
145                 150                 155                 160
Asn Gly Trp Asn Leu Leu Asp Phe Ile Ile Val Val Val Gly Leu Phe
                165                 170                 175
Ser Val Leu Leu Glu Gln Gly Pro Gly Arg Pro Gly Asp Ala Pro His
            180                 185                 190
Thr Gly Gly Lys Pro Gly Gly Phe Asp Val Lys Ala Leu Arg Ala Phe
        195                 200                 205
Arg Val Leu Arg Pro Leu Arg Leu Val Ser Gly Val Pro Ser Leu His
    210                 215                 220
Ile Val Val Asn Ser Ile Met Lys Ala Leu Val Pro Leu Leu His Ile
225                 230                 235                 240
Ala Leu Leu Val Leu Phe Val Ile Ile Ile Tyr Ala Ile Ile Gly Leu
                245                 250                 255
Glu Leu Phe Leu Gly Arg Met His Lys Thr Cys Tyr Phe Leu Gly Ser
            260                 265                 270
Asp Met Glu Ala Glu Glu Asp Pro Ser Pro Cys Ala Ser Ser Gly Ser
        275                 280                 285
Gly Arg Ser Cys Thr Leu Asn His Thr Glu Cys Arg Gly Arg Trp Pro
    290                 295                 300
Gly Pro Asn Gly Gly Ile Thr Asn Phe Asp Asn Phe Phe Phe Ala Met
305                 310                 315                 320
Leu Thr Val Phe Gln Cys Ile Thr Met Glu Gly Trp Thr Asp Val Leu
                325                 330                 335
Tyr Trp Met Gln Asp Ala Met Gly Tyr Glu Leu Pro Trp Val Tyr Phe
            340                 345                 350
Val Ser Leu Val Ile Phe Gly Ser Phe Phe Val Leu Asn Leu Val Leu
        355                 360                 365
Gly Val Leu Ser Gly Glu Phe Ser Lys Glu Arg Glu Lys Ala Lys Ala
    370                 375                 380
Arg Gly Asp Phe Gln Lys Leu Arg Glu Lys Gln Gln Met Glu Glu Asp
385                 390                 395                 400
Leu Arg Gly Tyr Leu Asp Trp Ile Thr Gln Ala Glu Glu Leu Asp Leu
                405                 410                 415
His Asp Pro Ser Val Asp Gly Asn Leu Ala Ser Leu Ala Glu Glu Gly
            420                 425                 430
Arg Ala Gly His Arg Pro Gln Leu Ser Glu Leu Thr Asn Arg Arg Arg
        435                 440                 445
Gly Arg Leu Arg Trp Phe Ser His Ser Thr Arg Ser Thr His Ser Thr
    450                 455                 460
Ser Ser His Ala Ser Leu Pro Ala Ser Asp Thr Gly Ser Met Thr Asp
465                 470                 475                 480
Thr Pro Gly Asp Glu Asp Glu Glu Glu Gly Thr Met Ala Ser Cys Thr
                485                 490                 495
Arg Cys Leu Asn Lys Ile Met Lys Thr Arg Ile Cys Arg His Phe Arg
            500                 505                 510
Arg Ala Asn Arg Gly Leu Arg Ala Arg Cys Arg Arg Ala Val Lys Ser
        515                 520                 525
Asn Ala Cys Tyr Trp Ala Val Leu Leu Leu Val Phe Leu Asn Thr Leu
    530                 535                 540
Thr Ile Ala Ser Glu His His Gly Gln Pro Leu Trp Leu Thr Gln Thr
545                 550                 555                 560
Gln Glu Tyr Ala Asn Lys Val Leu Leu Cys Leu Phe Thr Val Glu Met
                565                 570                 575
Leu Leu Lys Leu Tyr Gly Leu Gly Pro Ser Val Tyr Val Ala Ser Phe
            580                 585                 590
Phe Asn Arg Phe Asp Cys Phe Val Val Cys Gly Gly Ile Leu Glu Thr
        595                 600                 605
Thr Leu Val Glu Val Gly Ala Met Gln Pro Leu Gly Ile Ser Val Leu
    610                 615                 620
Arg Cys Val Arg Leu Leu Arg Ile Phe Lys Val Thr Arg His Trp Ala
625                 630                 635                 640
Ser Leu Ser Asn Leu Val Ala Ser Leu Leu Asn Ser Met Lys Ser Ile
                645                 650                 655
Ala Ser Leu Leu Leu Leu Leu Phe Leu Phe Ile Ile Ile Phe Ser Leu
            660                 665                 670
Leu Gly Met Gln Leu Phe Gly Gly Lys Phe Asn Phe Asp Gln Thr His
        675                 680                 685
Thr Lys Arg Ser Thr Phe Asp Thr Phe Pro Gln Ala Leu Leu Thr Val
    690                 695                 700
Phe Gln Ile Leu Thr Gly Glu Asp Trp Asn Val Val Met Tyr Asp Gly
705                 710                 715                 720
Ile Met Ala Tyr Gly Gly Pro Phe Phe Pro Gly Met Leu Val Cys Val
                725                 730                 735
Tyr Phe Ile Ile Leu Phe Ile Cys Gly Asn Tyr Ile Leu Leu Asn Val
            740                 745                 750
Phe Leu Ala Ile Ala Val Asp Asn Leu Ala Ser Gly Asp Ala Gly Thr
        755                 760                 765
Ala Lys Asp Lys Gly Arg Glu Lys Ser Ser Glu Gly Asn Pro Pro Lys
    770                 775                 780
Glu Asn Lys Val Leu Val Pro Gly Gly Glu Asn Glu Asp Ala Lys Gly
785                 790                 795                 800
Ala Arg Ser Glu Gly Ala Ala Pro Gly Met Glu Glu Glu Glu Glu Glu
                805                 810                 815
Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Asn Gly Ala
            820                 825                 830
Gly His Val Glu Leu Leu Gln Glu Val Val Pro Lys Glu Lys Val Val
        835                 840                 845
Pro Ile Pro Glu Gly Ser Ala Phe Phe Cys Leu Ser Gln Thr Asn Pro
    850                 855                 860
Leu Arg Lys Ala Cys His Thr Leu Ile His His His Ile Phe Thr Ser
865                 870                 875                 880
Leu Ile Leu Val Phe Ile Ile Leu Ser Ser Val Ser Leu Ala Ala Glu
                885                 890                 895
Asp Pro Ile Arg Ala His Ser Phe Arg Asn His Ile Leu Gly Tyr Phe
            900                 905                 910
Asp Tyr Ala Phe Thr Ser Ile Phe Thr Val Glu Ile Leu Leu Lys Met
        915                 920                 925
Thr Val Phe Gly Ala Phe Leu His Arg Gly Ser Phe Cys Arg Ser Trp
    930                 935                 940
Phe Asn Leu Leu Asp Leu Leu Val Val Ser Val Ser Leu Ile Ser Phe
945                 950                 955                 960
Gly Ile His Ser Ser Ala Ile Ser Val Val Lys Ile Leu Arg Val Leu
                965                 970                 975
Arg Val Leu Arg Pro Leu Arg Ala Ile Asn Arg Ala Lys Gly Leu Lys
            980                 985                 990
His Val Val Gln Cys Val Phe Val  Ala Ile Arg Thr Ile  Gly Asn Ile
        995                 1000                 1005
Met Ile  Val Thr Thr Leu Leu  Gln Phe Met Phe Ala  Cys Ile Gly
    1010                 1015                 1020
Val Gln  Leu Phe Lys Gly Lys  Phe Tyr Ser Cys Thr  Asp Glu Ala
    1025                 1030                 1035
Lys His  Thr Leu Lys Glu Ser  Lys Gly Ser Phe Leu  Ile Tyr Pro
    1040                 1045                 1050
Asp Gly  Asp Val Ser Arg Pro  Leu Val Arg Glu Arg  Leu Trp Val
    1055                 1060                 1065
Asn Ser  Asp Phe Asn Phe Asp  Asn Val Leu Ser Ala  Met Met Ala
    1070                 1075                 1080
Leu Phe  Thr Val Ser Thr Phe  Glu Gly Trp Pro Ala  Leu Leu Tyr
    1085                 1090                 1095
Lys Ala  Ile Asp Ala Asn Ala  Glu Asp Glu Gly Pro  Ile Tyr Asn
    1100                 1105                 1110
Tyr His  Val Glu Ile Ser Val  Phe Phe Ile Val Tyr  Ile Ile Ile
    1115                 1120                 1125
Ile Ala  Phe Phe Met Met Asn  Ile Phe Val Gly Phe  Val Ile Ile
    1130                 1135                 1140
Thr Phe  Arg Ala Gln Gly Glu  Gln Glu Tyr Gln Asn  Cys Glu Leu
    1145                 1150                 1155
Asp Lys  Asn Gln Arg Gln Cys  Val Glu Tyr Ala Leu  Lys Ala Gln
    1160                 1165                 1170
Pro Leu  Arg Arg Tyr Ile Pro  Lys Asn Pro His Gln  Tyr Arg Val
    1175                 1180                 1185
Trp Ala  Thr Val Asn Ser Arg  Ala Phe Glu Tyr Leu  Met Phe Leu
    1190                 1195                 1200
Leu Ile  Leu Leu Asn Thr Val  Ala Leu Ala Met Gln  His Tyr Glu
    1205                 1210                 1215
Gln Thr  Ala Pro Phe Asn Tyr  Ala Met Asp Ile Leu  Asn Met Val
    1220                 1225                 1230
Phe Thr  Gly Leu Phe Thr Ile  Glu Met Val Leu Lys  Ile Ile Ala
    1235                 1240                 1245
Phe Lys  Pro Lys His Tyr Phe  Ala Asp Ala Trp Asn  Thr Phe Asp
    1250                 1255                 1260
Ala Leu  Ile Val Val Gly Ser  Val Val Asp Ile Ala  Val Thr Glu
    1265                 1270                 1275
Val Asn  Asn Gly Gly His Leu  Gly Glu Ser Ser Glu  Asp Thr Ser
    1280                 1285                 1290
Arg Ile  Ser Ile Thr Phe Phe  Arg Leu Phe Arg Val  Met Arg Leu
    1295                 1300                 1305
Val Lys  Leu Leu Ser Lys Gly  Glu Gly Ile Arg Thr  Leu Leu Trp
    1310                 1315                 1320
Thr Phe  Ile Lys Ser Phe Gln  Ala Leu Pro Tyr Val  Ala Leu Leu
    1325                 1330                 1335
Ile Ala  Met Ile Phe Phe Ile  Tyr Ala Val Ile Gly  Met Gln Met
    1340                 1345                 1350
Phe Gly  Leu Val Ala Leu Gln  Asp Gly Thr Gln Ile  Asn Arg Asn
    1355                 1360                 1365
Asn Asn  Phe Gln Thr Phe Pro  Gln Ala Val Leu Leu  Leu Phe Arg
    1370                 1375                 1380
Cys Ala  Thr Gly Glu Ala Trp  Gln Glu Ile Met Leu  Ala Ser Leu
    1385                 1390                 1395
Pro Gly  Asn Arg Cys Asp Pro  Glu Ser Asp Phe Gly  Pro Gly Glu
    1400                 1405                 1410
Glu Phe  Thr Cys Gly Ser Ser  Phe Ala Ile Val Tyr  Phe Ile Ser
    1415                 1420                 1425
Phe Phe  Met Leu Cys Ala Phe  Leu Ile Ile Asn Leu  Phe Val Ala
    1430                 1435                 1440
Val Ile  Met Asp Asn Phe Asp  Tyr Leu Thr Arg Asp  Trp Ser Ile
    1445                 1450                 1455
Leu Gly  Pro His His Leu Asp  Glu Phe Lys Arg Ile  Trp Ser Glu
    1460                 1465                 1470
Tyr Asp  Pro Gly Ala Lys Gly  Arg Ile Lys His Leu  Asp Val Val
    1475                 1480                 1485
Ala Leu  Leu Arg Arg Ile Gln  Pro Pro Leu Gly Phe  Gly Lys Leu
    1490                 1495                 1500
Cys Pro  His Arg Val Ala Cys  Lys Arg Leu Val Ala  Met Asn Val
    1505                 1510                 1515
Pro Leu  Asn Ser Asp Gly Thr  Val Thr Phe Asn Ala  Thr Leu Phe
    1520                 1525                 1530
Ala Leu  Val Arg Thr Ser Leu  Lys Ile Lys Thr Glu  Gly Asn Leu
    1535                 1540                 1545
Asp Gln  Ala Asn Gln Glu Leu  Arg Met Val Ile Lys  Lys Ile Trp
    1550                 1555                 1560
Lys Arg  Ile Lys Gln Lys Leu  Leu Asp Glu Val Ile  Pro Pro Pro
    1565                 1570                 1575
Asp Glu  Glu Glu Val Thr Val  Gly Lys Phe Tyr Ala  Thr Phe Leu
    1580                 1585                 1590
Ile Gln  Asp Tyr Phe Arg Lys  Phe Arg Arg Arg Lys  Glu Lys Gly
    1595                 1600                 1605
Leu Leu  Gly Arg Glu Ala Pro  Thr Ser Thr Ser Ser  Ala Leu Gln
    1610                 1615                 1620
Ala Gly  Leu Arg Ser Leu Gln  Asp Leu Gly Pro Glu  Ile Arg Gln
    1625                 1630                 1635
Ala Leu  Thr Tyr Val Thr Glu  Glu Glu Glu Glu Glu  Glu Glu Ala
    1640                 1645                 1650
Val Gly  Gln Glu Ala Glu Glu  Glu Glu Ala Glu Asn  Asn Pro Glu
    1655                 1660                 1665
Pro Tyr  Lys Asp Ser Ile Asp  Ser Gln Pro Gln Ser  Arg Trp Asn
    1670                 1675                 1680
Ser Arg  Ile Ser Val Ser Leu  Pro Val Lys Glu Lys  Leu Pro Asp
    1685                 1690                 1695
Ser Leu  Ser Thr Gly Pro Ser  Asp Asp Asp Gly Leu  Ala Pro Asn
    1700                 1705                 1710
Ser Arg  Gln Pro Ser Val Ile  Gln Ala Gly Ser Gln  Pro His Arg
    1715                 1720                 1725
Arg Ser  Ser Gly Val Phe Met  Phe Thr Ile Pro Glu  Glu Gly Ser
    1730                 1735                 1740
Ile Gln  Leu Lys Gly Thr Gln  Gly Gln Asp Asn Gln  Asn Glu Glu
    1745                 1750                 1755
Gln Glu  Leu Pro Asp Trp Thr  Pro Asp Leu Asp Arg  Ala Gly Arg
    1760                 1765                 1770
Asp Ser  Phe Glu Pro Ser Pro  Phe Thr Thr Ser Leu  Val Gln Gln
    1775                 1780                 1785
His Val  Asn Gly His Met Ser  Thr Pro Thr Phe Ala  Ala Pro His
    1790                 1795                 1800
Ala Cys  Arg Ser Glu Pro Ser  Phe Thr Ile Gln Cys  Leu Gln Arg
    1805                 1810                 1815
Leu Gly  Ser Cys Glu Asp Leu  Pro Ile Pro Gly Thr  Tyr His Arg
    1820                 1825                 1830
Gly Arg  Thr Ser Gly Pro Ser  Arg Ala Gln Gly Ser  Trp Ala Ala
    1835                 1840                 1845
Pro Pro  Gln Lys Gly Arg Leu  Leu Tyr Ala Pro Leu  Leu Leu Val
    1850                 1855                 1860
Glu Glu  Ser Thr Val Gly Glu  Gly Tyr Leu Gly Lys  Leu Gly Gly
    1865                 1870                 1875
Pro Leu  Arg Thr Phe Thr Cys  Leu Gln Val Pro Gly  Ala His Pro
    1880                 1885                 1890
Asn Pro  Ser His Arg Lys Arg  Gly Ser Ala Asp Ser  Leu Val Glu
    1895                 1900                 1905
Ala Val  Leu Ile Ser Glu Gly  Leu Gly Leu Phe Ala  Gln Asp Pro
    1910                 1915                 1920
Arg Phe  Val Ala Leu Ala Lys  Gln Glu Ile Ala Asp  Ala Cys His
    1925                 1930                 1935
Leu Thr  Leu Asp Glu Met Asp  Ser Ala Ala Ser Asp  Leu Leu Ala
    1940                 1945                 1950
Gln Arg  Thr Ile Ser Leu Tyr  Ser Asp Glu Glu Ser  Ile Leu Ser
    1955                 1960                 1965
Arg Phe  Asp Glu Glu Asp Leu  Gly Asp Glu Met Ala  Cys Val His
    1970                 1975                 1980
Ala Leu
    1985
 
           
             7 
             20 
             DNA 
             homo sapiens 
           
            7
tttctctctg tctaccttgt                                                 20
 
           
             8 
             21 
             DNA 
             homo sapiens 
           
            8
ctgcgggctc ccttactact g                                               21
 
           
             9 
             20 
             DNA 
             Mus musculus 
           
            9
atctggtggc atctttgctc                                                 20
 
           
             10 
             20 
             DNA 
             Mus musculus 
           
            10
agcagccagg gacacactac                                                 20
 
           
             11 
             20 
             DNA 
             Mus musculus 
           
            11
ggcgagagtt cagaggacag                                                 20
 
           
             12 
             20 
             DNA 
             Mus musculus 
           
            12
ccacatccaa gtgttgatgc                                                 20
 
           
             13 
             18 
             DNA 
             Mus musculus 
           
            13
ggatcaagcc aaccagga                                                   18
 
           
             14 
             18 
             DNA 
             Mus musculus 
           
            14
ctttggttcc cttgggct                                                   18
 
           
             15 
             20 
             DNA 
             Mus musculus 
           
            15
ttccggagaa ggaaagaaaa                                                 20
 
           
             16 
             19 
             DNA 
             Mus musculus 
           
            16
cacaaatcgt gggtcttgg                                                  19
 
           
             17 
             20 
             DNA 
             Mus musculus 
           
            17
actcaagatg acagtgtttg                                                 20
 
           
             18 
             20 
             DNA 
             Mus musculus 
           
            18
cctggtttcc agcactgtgt                                                 20
 
           
             19 
             20 
             DNA 
             Mus musculus 
           
            19
actgaaccat accgagtgcc                                                 20
 
           
             20 
             20 
             DNA 
             Mus musculus 
           
            20
tcagcctgtg tgatccagtc                                                 20
 
           
             21 
             20 
             DNA 
             Mus musculus 
           
            21
atgaaaacaa ggatctgccg                                                 20
 
           
             22 
             20 
             DNA 
             Mus musculus 
           
            22
gagacgtaca catcggagca                                                 20
 
           
             23 
             18 
             DNA 
             Mus musculus 
           
            23
acacaggaga agctctgg                                                   18
 
           
             24 
             17 
             DNA 
             Mus musculus 
           
            24
cacctcactg gtcagca                                                    17
 
           
             25 
             25 
             DNA 
             Mus musculus 
           
            25
catggcatcc tgcatccagt agagg                                           25
 
           
             26 
             26 
             DNA 
             Mus musculus 
           
            26
gtccgaggaa tagctcgagt ccgatg                                          26
 
           
             27 
             26 
             DNA 
             Mus musculus 
           
            27
ctcccaacca cacaggagaa gctctg                                          26
 
           
             28 
             26 
             DNA 
             Mus musculus 
           
            28
cccctgttgt tggtggagga atctac                                          26
 
           
             29 
             20 
             DNA 
             homo sapiens 
           
            29
gagaatcctt ccatccctgc                                                 20
 
           
             30 
             20 
             DNA 
             Homo sapiens 
           
            30
attcgtccaa ggaacagctc                                                 20
 
           
             31 
             20 
             DNA 
             Homo sapiens 
           
            31
gtggagacgg tgctcaagat                                                 20
 
           
             32 
             20 
             DNA 
             Homo sapiens 
           
            32
attcgtccaa ggaacagctc                                                 20
 
           
             33 
             19 
             DNA 
             Homo sapiens 
           
            33
tcgtgctctc gtcatcatc                                                  19
 
           
             34 
             20 
             DNA 
             Homo sapiens 
           
            34
tggagtgtgt ggagcgagta                                                 20
 
           
             35 
             19 
             DNA 
             Homo sapiens 
           
            35
accaatagga ggcgtggac                                                  19
 
           
             36 
             20 
             DNA 
             Homo sapiens 
           
            36
ggtgtgggtc tggtcaaagt                                                 20
 
           
             37 
             21 
             DNA 
             Homo sapiens 
           
            37
ttctcctctt cctctcatca t                                               21
 
           
             38 
             19 
             DNA 
             Homo sapiens 
           
            38
ggtttggctg aggcagaag                                                  19
 
           
             39 
             20 
             DNA 
             Homo sapiens 
           
            39
tgtacccaag gagaaggtgg                                                 20
 
           
             40 
             20 
             DNA 
             Homo sapiens 
           
            40
aagtgatgat gacgaagccc                                                 20
 
           
             41 
             20 
             DNA 
             Homo sapiens 
           
            41
ccatctcggt ggtgaagatt                                                 20
 
           
             42 
             19 
             DNA 
             Homo sapiens 
           
            42
cggatccctt caccctact                                                  19
 
           
             43 
             22 
             DNA 
             Homo sapiens 
           
            43
taccgtgtgg agatctcagt gt                                              22
 
           
             44 
             22 
             DNA 
             Homo sapiens 
           
            44
caaccacatc caagtgtttg at                                              22
 
           
             45 
             22 
             DNA 
             Homo sapiens 
           
            45
gcatttccat taccttcttt cg                                              22
 
           
             46 
             22 
             DNA 
             Homo sapiens 
           
            46
caaccacatc caagtgtttg at                                              22
 
           
             47 
             19 
             DNA 
             Homo sapiens 
           
            47
caccagagat ggtccatcc                                                  19
 
           
             48 
             20 
             DNA 
             Homo sapiens 
           
            48
ggggatgacc tcatctagca                                                 20
 
           
             49 
             23 
             DNA 
             Homo sapiens 
           
            49
tgaaaaggac tggaaactaa caa                                             23
 
           
             50 
             19 
             DNA 
             Homo sapiens 
           
            50
gccatctcgt ctcccaagt                                                  19
 
           
             51 
             20 
             DNA 
             Homo sapiens 
           
            51
ccaccctccc atacaacact                                                 20
 
           
             52 
             19 
             DNA 
             Homo sapiens 
           
            52
gtgattggtt cttgtcccc                                                  19
 
           
             53 
             20 
             DNA 
             Homo sapiens 
           
            53
gatcaggtag gaagcagcca                                                 20
 
           
             54 
             20 
             DNA 
             Homo sapiens 
           
            54
ctcctggtac cctgatgacc                                                 20
 
           
             55 
             20 
             DNA 
             Homo sapiens 
           
            55
gaggttccca agggagtagg                                                 20
 
           
             56 
             20 
             DNA 
             Homo sapiens 
           
            56
gtctggctgg aaggagtgag                                                 20
 
           
             57 
             20 
             DNA 
             Homo sapiens 
           
            57
ctcggtcctg actatgctcc                                                 20
 
           
             58 
             20 
             DNA 
             Homo sapiens 
           
            58
ggtaggaagg cgactagggt                                                 20
 
           
             59 
             18 
             DNA 
             Homo sapiens 
           
            59
atcccaaggc ctgacctc                                                   18
 
           
             60 
             18 
             DNA 
             Homo sapiens 
           
            60
accctccacc tccgacct                                                   18
 
           
             61 
             20 
             DNA 
             Homo sapiens 
           
            61
ctgaccccgc ccttatttct                                                 20
 
           
             62 
             20 
             DNA 
             Homo sapiens 
           
            62
agcattggat ctaggaaccg                                                 20
 
           
             63 
             19 
             DNA 
             Homo sapiens 
           
            63
actgagagtg ggcctgctt                                                  19
 
           
             64 
             19 
             DNA 
             Homo sapiens 
           
            64
gtgcagcctt gagctctgt                                                  19
 
           
             65 
             20 
             DNA 
             Homo sapiens 
           
            65
ggatgcatgc cttttctctc                                                 20
 
           
             66 
             20 
             DNA 
             Homo sapiens 
           
            66
gtttgccagg cacaaagaag                                                 20
 
           
             67 
             20 
             DNA 
             Homo sapiens 
           
            67
tgtggctgga gtgatgaaag                                                 20
 
           
             68 
             20 
             DNA 
             Homo sapiens 
           
            68
ggagggcaga ccacatctaa                                                 20
 
           
             69 
             20 
             DNA 
             Homo sapiens 
           
            69
aattgtcctt ctctccctgc                                                 20
 
           
             70 
             18 
             DNA 
             Homo sapiens 
           
            70
cagcctggct ggaccccc                                                   18
 
           
             71 
             20 
             DNA 
             Homo sapiens 
           
            71
aggtcctgac cactatcccc                                                 20
 
           
             72 
             20 
             DNA 
             Homo sapiens 
           
            72
ggacttgagt cagggtttgg                                                 20
 
           
             73 
             20 
             DNA 
             Homo sapiens 
           
            73
tttacgacac acacctccca                                                 20
 
           
             74 
             20 
             DNA 
             Homo sapiens 
           
            74
cacctaccta agcctgccct                                                 20
 
           
             75 
             20 
             DNA 
             Homo sapiens 
           
            75
agggcaggct taggtaggtg                                                 20
 
           
             76 
             20 
             DNA 
             Homo sapiens 
           
            76
agaaggaata ggaggctggg                                                 20
 
           
             77 
             20 
             DNA 
             Homo sapiens 
           
            77
gatcatccct gcctctctcc                                                 20
 
           
             78 
             20 
             DNA 
             Homo sapiens 
           
            78
cttccccctc ccctaataca                                                 20
 
           
             79 
             18 
             DNA 
             Homo sapiens 
           
            79
agcctamgag cccaacct                                                   18
 
           
             80 
             18 
             DNA 
             Homo sapiens 
           
            80
acccatccca tggtctcc                                                   18
 
           
             81 
             20 
             DNA 
             Homo sapiens 
           
            81
gagctccaca gtgacttccc                                                 20
 
           
             82 
             20 
             DNA 
             Homo sapiens 
           
            82
accctgccta tagaccaccc                                                 20
 
           
             83 
             20 
             DNA 
             Homo sapiens 
           
            83
gtggtctata ggcagggtgc                                                 20
 
           
             84 
             19 
             DNA 
             Homo sapiens 
           
            84
gactgtgtag gggtggagc                                                  19
 
           
             85 
             20 
             DNA 
             Homo sapiens 
           
            85
atgggaccca agaaaggtct                                                 20
 
           
             86 
             19 
             DNA 
             Homo sapiens 
           
            86
gtgggatggg aggtgtaga                                                  19
 
           
             87 
             19 
             DNA 
             Homo sapiens 
           
            87
cctcaccatg atgactccc                                                  19
 
           
             88 
             17 
             DNA 
             Homo sapiens 
           
            88
tgtctgccga gctcmcc                                                    17
 
           
             89 
             20 
             DNA 
             Homo sapiens 
           
            89
caaacactgt tctgggtgct                                                 20
 
           
             90 
             19 
             DNA 
             Homo sapiens 
           
            90
ctcctccatg ctcctccac                                                  19
 
           
             91 
             20 
             DNA 
             Homo sapiens 
           
            91
tcagggccag aactgtatcc                                                 20
 
           
             92 
             20 
             DNA 
             Homo sapiens 
           
            92
gtcccctcag ctcctagctc                                                 20
 
           
             93 
             18 
             DNA 
             Homo sapiens 
           
            93
ctccccgctc tttcacac                                                   18
 
           
             94 
             19 
             DNA 
             Homo sapiens 
           
            94
gactggggtc ccatagtca                                                  19
 
           
             95 
             20 
             DNA 
             Homo sapiens 
           
            95
tccccaggtc tgagtctagc                                                 20
 
           
             96 
             18 
             DNA 
             Homo sapiens 
           
            96
gtcctgtggg tttgggtg                                                   18
 
           
             97 
             20 
             DNA 
             Homo sapiens 
           
            97
gtagccatat gcttgggtgc                                                 20
 
           
             98 
             18 
             DNA 
             Homo sapiens 
           
            98
agtcttggga ggggtcct                                                   18
 
           
             99 
             20 
             DNA 
             Homo sapiens 
           
            99
agttcctcac ccctcctcac                                                 20
 
           
             100 
             20 
             DNA 
             Homo sapiens 
           
            100
ctgcctcatc ccctgataaa                                                 20
 
           
             101 
             19 
             DNA 
             Homo sapiens 
           
            101
atttaggggt cttggggtg                                                  19
 
           
             102 
             20 
             DNA 
             Homo sapiens 
           
            102
gcagccttaa atgttcccaa                                                 20
 
           
             103 
             19 
             DNA 
             Homo sapiens 
           
            103
cagtgcaaga ggttgacca                                                  19
 
           
             104 
             20 
             DNA 
             Homo sapiens 
           
            104
cccaaggaat tcatccactg                                                 20
 
           
             105 
             20 
             DNA 
             Homo sapiens 
           
            105
gctttgagaa gacagggcac                                                 20
 
           
             106 
             20 
             DNA 
             Homo sapiens 
           
            106
gaaagccagt agagggggac                                                 20
 
           
             107 
             20 
             DNA 
             Homo sapiens 
           
            107
gtaatgaccc caccatcacc                                                 20
 
           
             108 
             20 
             DNA 
             Homo sapiens 
           
            108
cagagggaca tgggaaaaga                                                 20
 
           
             109 
             20 
             DNA 
             Homo sapiens 
           
            109
aaatgcaaac tgagcatccc                                                 20
 
           
             110 
             18 
             DNA 
             Homo sapiens 
           
            110
amggaaatgg gtatggca                                                   18
 
           
             111 
             20 
             DNA 
             Homo sapiens 
           
            111
gactgcatct cccagtaggc                                                 20
 
           
             112 
             20 
             DNA 
             Homo sapiens 
           
            112
attcttaacc catcccctgc                                                 20
 
           
             113 
             20 
             DNA 
             Homo sapiens 
           
            113
gtaggggtgg caggtagaca                                                 20
 
           
             114 
             20 
             DNA 
             Homo sapiens 
           
            114
gtggcagggg agtgagtaga                                                 20
 
           
             115 
             20 
             DNA 
             Homo sapiens 
           
            115
gatgtagccc ctggtgagaa                                                 20
 
           
             116 
             19 
             DNA 
             Homo sapiens 
           
            116
ggtggtgtga ggaaatggt                                                  19
 
           
             117 
             20 
             DNA 
             Homo sapiens 
           
            117
acagtgttct gcccttcacc                                                 20
 
           
             118 
             20 
             DNA 
             Homo sapiens 
           
            118
aactggaggg cagtcagaga                                                 20
 
           
             119 
             20 
             DNA 
             Homo sapiens 
           
            119
cagtggtacc tccccaactc                                                 20
 
           
             120 
             20 
             DNA 
             Homo sapiens 
           
            120
agaaacctct gaggatgcga                                                 20
 
           
             121 
             20 
             DNA 
             Homo sapiens 
           
            121
acattcgttc ctgcataccc                                                 20
 
           
             122 
             18 
             DNA 
             Homo sapiens 
           
            122
atgagmgctc cttgcacc                                                   18
 
           
             123 
             20 
             DNA 
             Homo sapiens 
           
            123
tcttcctatt ggctcatgcc                                                 20
 
           
             124 
             18 
             DNA 
             Homo sapiens 
           
            124
ggggcctcag mccttatc                                                   18
 
           
             125 
             20 
             DNA 
             Homo sapiens 
           
            125
acctatttct ccacccccac                                                 20
 
           
             126 
             20 
             DNA 
             Homo sapiens 
           
            126
gcttcttccc agaagcagtg                                                 20
 
           
             127 
             20 
             DNA 
             Homo sapiens 
           
            127
gtgcatgcaa cactcagtcc                                                 20
 
           
             128 
             20 
             DNA 
             Homo sapiens 
           
            128
ctcaacttcc tgcctcctga                                                 20
 
           
             129 
             20 
             DNA 
             Homo sapiens 
           
            129
atctggtctg cctaacgtgc                                                 20
 
           
             130 
             20 
             DNA 
             Homo sapiens 
           
            130
gagatggggc acaaacagtc                                                 20
 
           
             131 
             20 
             DNA 
             Homo sapiens 
           
            131
gactgtttgt gccccatctc                                                 20
 
           
             132 
             20 
             DNA 
             Homo sapiens 
           
            132
ttccccagat ctctgtcctg                                                 20
 
           
             133 
             20 
             DNA 
             Homo sapiens 
           
            133
ctgacattgc tatttgcccc                                                 20
 
           
             134 
             20 
             DNA 
             Homo sapiens 
           
            134
aaagggcctg atatgtgctg                                                 20
 
           
             135 
             20 
             DNA 
             Homo sapiens 
           
            135
agcggtgagt cctagaccct                                                 20
 
           
             136 
             20 
             DNA 
             Homo sapiens 
           
            136
gactcctttc cgtcctcctc                                                 20
 
           
             137 
             20 
             DNA 
             Homo sapiens 
           
            137
cgtcaacact gatcccacct                                                 20
 
           
             138 
             20 
             DNA 
             Homo sapiens 
           
            138
caaaatccag ggatgtggtc                                                 20